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We should accustom ourselves to the idea that a primary
deficiency of insulin is only one, and then not the
commonest cause of the diabetic syndrome.
H. Himsworth
1949
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ABSTRACT
The control of carbohydrate metabolism depends not only upon the
concentrations of circulating hormones but also upon the
responsiveness of target organ tissues. Following the demonstration
of insulin receptors upon circulating monocytes, it became widely
believed that the insulin receptor status of the important target
organ tissues was mirrored by peripheral blood monocytes. Clinical
states of insulin resistance were thus categorised as being related
to either receptor or post-binding defects by the results of monocyte
insulin receptor assays. The studies described in this thesis were
designed to examine the clinical relevance of monocyte insulin
receptor status and to define the nature of peripheral tissue insulin
resistance in hepatic cirrhosis, chronic renal failure,
hyperthyroidism and brittle diabetes.
The adipocyte and monocyte insulin receptor assays were
optimised with respect to accuracy, precision, level of non-specific
binding and maintenance of steady state binding. The two assays were
then used to examine normal and insulin resistant subjects. No
correlation between the insulin receptor status of the two tissues
could be demonstrated in any group of subjects studied. All
subsequent studies were performed using adipose tissue as an example
of a peripheral, insulin sensitive tissue.
Subjects with hepatic cirrhosis were found to be markedly
insulin resistant in vivo and adipocyte insulin receptor number was
decreased in the cirrhotic subjects, especially in those with
alcoholic cirrhosis. Adipocyte resistance Lo insulin stimulation of
lipogenesis was present regardless of aetiology. In chronic renal
failure, insulin resistance was evidenced by fasting hyperglycaemia
and impaired glucose tolerance in the presence of normal serum
immunoreactive insulin levels. Adipocyte insulin receptor number was
found to be decreased, but receptor affinity was supra-normal. This
unusual insulin receptor status was associated with normal adipocyte
insulin sensitivity. Continuous ambulatory peritoneal dialysis was
found to be associated with improved blood glucose control and normal
adipocyte insulin receptor affinity and insulin sensitivity.
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In hyperthyroidism, adipocyte sensitivity to stimulation of
lipogenesis and glucose transport was found to be normal although
adipocyte insulin receptor number was markedly decreased. These
findings suggest that thyroid hormones may modulate insulin receptor
number and also that adaptation of the post-binding steps of insulin
action prevents the theoretical consequence of decreased insulin
receptor number in this condition. The presumed in vivo insulin
resistance in hyperthyroidism appears to relate to hepatic rather
than peripheral tissue abnormalities.
A group of subjects with brittle insulin-dependent diabetes were
observed to have decreased adipocyte insulin receptor affinity and
decreased sensitivity to insulin stimulation of lipogenesis compared
with matched groups of stable insulin-dependent diabetic and normal
subjects. These abnormalities were found to remit after periods of
stable metabolic control achieved by continuous intraperitoneal or
intravenous insulin infusion. Thus, tissue insulin resistance is
unlikely to be the primary cause of the pronounced metabolic
disturbances of brittle diabetes, although once present may
exacerbate the clinical syndrome.
In summary, the work presented in this thesis demonstrates that
monocytes may not be used as indicators of the insulin receptor
status of target organ cells, and that separate factors must control
receptor and post-binding steps in cellular insulin action. The
insulin resistance of chronic renal failure appears to be related to
circulating inhibitors of insulin action, in contrast, to that of
hepatic cirrhosis and brittle diabetes in which binding and post-
binding abnormalities of adipocyte insulin action were demonstrated.
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GENERAL BACKGROUND
The discovery of insulin by Banting and colleagues (1922)
revolutionised the management of diabetes mellitus and reinforced the
concept that the diabetic syndrome resulted from hormone deficiency.
Over the subsequent decade the dramatic effects of insulin therapy
were self-evident, although clinical observation suggested that
insulin did not bring about a uniform response in all cases of
diabetes mellitus (Orator 1927, Falta & Boiler 1931). In healthy men,
individual variation in the response to exogenous insulin was
documented (Himsworth 1935). Shortly afterwards, diabetic subjects
were found to differ markedly in glycaemic response following
intravenous insulin administered at the same time as oral glucose
(Himsworth & Kerr 1939). This test divided the diabetic subjects into
two distinct groups, those sensitive to insulin and those relatively
insensitive to insulin. Himsworth observed that the insulin
insensitive subject was typically obese and often had
arteriosclerotic complications. In such subjects, the disease was
less likely to have had a sudden onset. It was also shown that
insulin sensitivity could be modified by variation in the
carbohydrate content of the diet and by treatment of the insulin
insensitive state of Cushing's syndrome. This early suggestion that
the response to insulin could be affected by changes in hormonal or
metabolic state stimulated the debate about the aetiology of the
glucose intolerance observed in chronic liver disease (Naunyn 1906,
Rankin et^ scl 1953), uraemia (Linder e_t al^ 1925) and states of steroid
hormone, growth hormone and thyroid hormone excess (Conn & Fajans
1956, Cerasi & Luft 1964, Hales & Hyams 1964).
Following the development of radioimmunoassay for insulin,
demonstration of raised serum immunoreactive insulin levels in
chronic liver disease (Megyesi et_ al_ 1967), uraemia (Hampers et_ al_
1968), Cushing's syndrome (Pupo e_t^ al 1966), acromegaly (Beck £t_ al^
1965) and thyrotoxicosis (Doar et_ al_ 1969) suggested that insulin
insensitivity rather than insulin deficiency was the primary cause of
the impaired glucose tolerance associated with these conditions. The
abnormal response to insulin was variously attributed to circulating
insulin antagonists (Ensinck et al 1965) or to altered substrate
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supply (Raridle et al 1966). Accumulation of detailed information upon
cellular hormone receptors provided impetus for the concept that
insulin receptor abnormalities could account for states of insulin
insensitivity. This hypothesis became a central theme of research into
insulin action (Freychet et al 1971a, Olefsky 1976, Beck-Nielsen et_
al 1978).
HISTORY OF THE CELLULAR RECEPTOR CONCEPT
The concept of specific receptors for chemical messengers was
first postulated by Langley (1878 & 1905) who suggested that drugs
and hormones did not act directly upon biological processes but that
some receptive substance mediated the cellular effects. Ehrlich
(1913) extended the concept, naming the specific chemical groupings
"receptors". A direct relationship between the number of occupied
receptors and intensity of drug action was hypothesized by Gaddum
(1926) and Clark (1937). The observation that the maximal response to
a drug could be obtained by occupation of only a proportion of drug
receptors (Stephenson 1956) led to a more dynamic picture of ligand-
receptor interaction. Monod, Wyman and Changeux (1965) and Rubin and
Changeux (1966) proposed that the properties of a receptor could be
modified by binding of ligand to neighbouring receptors.
Advances in hormone receptor physiology were largely of a
theoretical nature until the advent of radio-labelled hormones of
high specific activity. The first such compound was tritiated
oestradiol which was shown to be retained specifically in the nucleus
of target tissues (Glasscock & Hoekstra 1959, Edelman et_ ski 1963). It
was later shown that the steroid was binding in a stereospecific
manner to a protein which could be isolated by density gradient
centrifugation (Toft et jil_ 1967). Intracellular receptor proteins for
the major steroid hormones had been identified by 1970, and
pathological states such as testicular feminisation in mice and male
psuedohermaphroditism in humans were soon associated with steroid
receptor abnormalities (Bullock & Bardin 1972).
It became apparent at an early stage that peptide hormones
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differed from steroid hormones in that the cell plasma membrane was
most probably the major site of action (Levine 1965, Pastan e_£ al^
1966). Cuatrecasas (1969) reported that insulin, bound covalently to
Sepharose beads too large to be endocytosed, could increase glucose
oxidation and inhibit lipolysis in isolated fat cells. Although this
work was shown to be technically flawed (Davidson et al 1972, Fritz
1972), other experimental evidence was soon forthcoming (Jarrett &
Smith 1974).
Radio-labelled insulin had been used in the radioimmunoassay for
insulin since 1960 (Yalow & Berson 1960) but uncertainty about the
biological activity and binding behaviour of the iodinated molecules
limited the applicability of such preparations for binding studies.
In 1971, a technique for the preparation of a mono-iodinated insulin
was described (Freychet et aj^ 1971b). This compound was almost as
active as native insulin in stimulating glucose oxidation in isolated
fat cells. With the development of a satisfactory probe of insulin
receptor function, detailed exploration of the characteristics of the
insulin receptor in different tissues could be undertaken.
INSULIN RECEPTOR PHYSIOLOGY
a)Molecular structure of the insulin receptor
Early work by Cuatrecasas (1973) established that the insulin
receptor was a membrane associated glycoprotein of molecular weight
around 300,000 Daltons. Jacobs and colleagues (1979) and Pilch and
Czech (1979) demonstrated that the receptor was composed of subunits
linked by disuphide bonds. Further work established that the insulin
receptor consists of two oc subunits (125,000 Daltons) which carry the
insulin binding sites and two subunits (95,000 Daltons) which are
involved in transmission of the insulin signal (Roth & Cassel 1983).
b)Specific binding
The universal property of receptors is their ability to
recognise and bind a specific ligand in the presence of a vast excess
of other molecules. Insulin analogues inhibit the binding of 125j_
insulin to a degree corresponding to their structural similarity to
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insulin itself. Thus desnonapeptide proinsulin, proinsulin and
desoctapeptide insulin display 12%, 4% and 1% of the binding
displacement activity of native insulin respectively, and these
percentages correspond to the bioactivity of the analogues in rat
adipocytes (Freychet et al 1974). Glucagon and other peptide hormones
were found not to inhibit binding of ^25p-insulin (Freychet et al
1971, Cuatrecasas 1971a).
As insulin receptors were envisaged as being responsible for the
binding of both labelled and unlabelled hormone, the finding that
some binding of labelled insulin always occured even at extremely
high native hormone concentrations required explanation. The concept
of non-specific binding developed (Cuatrecasas 1971a). The capacity
of the receptors is finite but the potential capacity for non¬
specific adherence of hormone to cell membrane or other biological
material is theoretically non-saturable. Hence, when all the
receptors are occupied by native hormone, the binding of labelled
insulin to cells or membranes must be accounted for by "non-specific"
binding. The binding observed in the presence of 10-^ molar
unlabelled hormone concentration is subtracted from the total binding
observed at any total hormone concentration in order to derive the
specific binding fraction.
c) Kinetics
The insulin - receptor interaction in vitro was shown to be
rapid and reversible (Cuatrecasas 1971b & 1972), characteristics that
were predicted from the relatively rapid onset and cessation of the
cellular action of insulin (Gliemann 1968). Dissociation of the
adipocyte insulin-receptor complex was found to be a first order
process and furthermore when labelled insulin was eluted from binding
sites on fat cell membranes, both the hormone and the receptor
retained their specific properties. The rates of association and
dissociation were both found to be decreased at low temperatures, but
as the latter was decreased to a greater extent, binding to isolated
fat cell membranes was found to be higher at 5°C than 37°C
(Cuatrecasas 1971b). Degradation of the labelled insulin, a slow
process at low temperatures, complicated the results of binding
experiments performed at 37°C. In particular, steady state binding to
isolated rat liver cells could not be achieved at 37°C (Freychet et
al 1974) or to solubilized insulin receptors from rat liver membranes
(Cuatrecasas 1972). Gammeltoft and Gliemann (1973) were, however,
able to demonstrate steady state binding to isolated rat adipocytes
at 37°C, possibly related to a lower total insulin degradation in
this system (Gliemann & Sonne 1978).
d) Spare receptor concept
The classical pharmacological concept of receptor mediated
biological effects was that of a direct relationship between receptor
occupancy and biological effect. Thus a maximal response would be
expected when all the receptors were occupied. However, Stevenson
(1956) observed that there appeared to be more drug receptors than
required for maximal response. Kono and Barham (1971) showed that
this was also the case for insulin receptors. They observed maximal
stimulation of glucose oxidation when only one-fortieth of the
binding sites were filled and that a 98% decrease in binding capacity
brought about by tryptic digestion did not reduce the maximum effect
of insulin but increased the insulin concentration necessary for it
to be achieved. The teleological significance of the presence of
spare receptors was seen as allowing a greater sensitivity of target
cells to low concentrations of hormone. Different tissues have been
observed to require different degrees of receptor occupancy for a
maximum response to insulin, from 2.5% in rat adipocytes (Kono &
Barham 1971) to 35% in rat hepatocytes (Frank et_ al_ 1981).
e) Negative cooperativity
Early studies of insulin - receptor interaction yielded results
suggestive of a homogenous species of insulin receptors, and it was
assumed that the affinity was fixed (Cuatrecasas 1972). However,
DeMeyts and colleagues (1973) demonstrated that as the occupancy of
the insulin receptor increased, the affinity of the receptors
decreased, resulting in acceleration of the dissociation rate of
insulin from receptor. The precise physiological role of this
phenomenon, referred to as negative cooperativity, remains unclear,
but it could provide a mechanism for buffering the target cell
against sustained elevations in circulating hormone levels and as an
amplification of the response to low hormone concentrations. Negative
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cooperativity provides a potential mechanism for regulation of
receptor affinity, but changes in receptor number may also be brought
about by incubation of cells in the presence of insulin (Gavin et al
1974). The in vitro phenomenon of downregulation has been
extrapolated to explain observations of decreased cellular receptor
number in both animals (Soli e£ al 1975, Freychet. et al_ 1972) and man
(Bar et_ al^ 197 6).
Analysis of insulin binding data by the method of Scatchard (1949)
yields curvilinear plots consistent with the concept of negative
cooperativity. The shape of the Scatchard plot would also be consistent
with the presence of two or more distinct classes of binding sites
(Kahn et al 1974) and although this possibility remains, the balance of
experimental evidence remains in favour of negative cooperativity
between a homogenous population of receptors (DeMeyts 1980).
f) Internalisation
Following the demonstration of the linkage between specific
binding of insulin and its degradation (Terris & Steiner 1975) it
became clear that the insulin - receptor interaction was more
complicated than a simple cell-surface bimolecular reversible
reaction. Insulin conjugated to fluorescent lactalbumin was observed
to bind to mouse fibroblasts diffusely at 4°C, but in clusters on the
cell membrane at higher temperatures (Schlessenger eh^ al^ 1978), raising
possible parallels with the macroglobulin receptors which when occupied
form invaginated clusters on the cell surface (Willingham et_ a_l 1979).
Clustering of occupied receptor is theoretically attractive, providing a
means of regulating the insulin receptor concentration and a mechanism for
efficient adsorptive pinocytosis.
Autoradiographic techniques using ^^I-insulin unequivocally
demonstrate that the hormone is internalised by hepatocytes. At
steady state binding approximately one half of the insulin is bound
to the hepatocyte cell membrane and the remainder has been
internalised (Gorden et a_l 1978). In rat adipocytes, approximately
50% has been internalised at steady state binding (Olefsky e_£ al
1982b). After internalisation, the hormone-receptor complex appears
to fuse with lysosomes (Carpentier et al 1979). The receptor mediated
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degradation of ligand is inhibited by agents such as ammonium
chloride and choroquine which inhibit lysosomal enzyme action (Gordon
et al 1980, Whittaker et al 1981a). After cleavage of ligand from
receptor, the receptor recycles and returns to the cell membrane.
(Steer & Ashwell 1980). novo receptor synthesis is not required
for the continued appearance of receptor at the hepatocyte cell
surface (Whittaker 1984). The processes of receptor clustering,
internalisation and recycling are obviously vital to regulation of
cellular receptor behaviour, but it would appear that they are divorced
from the events leading to the intracellular manifestations of hormone
action. When internalisation is impaired or when recycling is
inhibited, insulin action is not prevented (LeCam et al 1979, Hammons &
Jarrett 1979).
CLINICAL STUDIES OF INSULIN RECEPTORS
a) Techniques
The discovery by Gavin and co-workers (1972) of specific insulin
binding to human leucocytes opened up the field of clinical
investigation of insulin receptor physiology. They observed that the
affinity of insulin binding to leucocytes appeared to be similar to
that exhibited by hepatocytes and adipocytes. In addition, the degree
to which insulin analogues could displace ^^1-insulin from the
leucocyte receptor varied with the ability of the analogue to
stimulate glucose oxidation in rat adipocytes (Freychet 1971a).
Subsequent studies of leucocyte insulin binding in states of insulin
resistance gave results suggestive of an abnormality of insulin
binding, but the data were not unequivocal (Archer et_ arl 1973). In
1975, Schwartz (1975) demonstrated that monocytes were responsible
for the greater part of the insulin binding capacity of mixed
leucocyte preparations. Expression of the observed binding data per
unit number of monocytes, rather than total leucocytes, resulted in a
clearer separation of binding results from normal and insulin
resistant patients. Beck-Nielsen and colleagues (1977) confirmed that
monocytes accounted for the major part of the insulin binding
capacity of peripheral blood cells, and further demonstrated the
relative insulin binding behaviour of lymphocytes, polymorphonuclear
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leucocytes, erythrocytes and platelets. The discovery of specific
insulin receptors on human erythrocytes attracted much interest as
this offered a method for estimating insulin receptor status without
venesection of large volumes of blood (Gambhir et al 1977). The
erythrocyte insulin receptor appeared to display similar kinetic
characteristics to that of rat hepatocytes and human monocytes.
Measurement of specific insulin binding to human adipocytes was
achieved over a decade ago (Marinetti et al 1972, Olefsky et al
1974), although these pioneer studies were complicated by problems of
high non-specific binding, uncertain cell viability and lack of steady
state binding. The development of an improved method of isolating and
handling human adipocytes allowed examination at physiological
temperature and pH of steady state insulin binding (Pedersen 1982a).
b) Physiological regulation of insulin receptors
Diurnal changes have been observed in blood cell insulin binding
(Beck-Nielsen & Pedersen 1978). They were abolished by starvation,
and insulin receptors on monocytes and erythrocytes exhibited rapid
down-regulation following food intake. Chronic changes in monocyte
receptor number have been observed after hypercaloric and hypocaloric
dieting (Beck-Nielsen et_ al_ 1978 & 1980). Isocaloric diets rich in
fat or sucrose brought about a reduction in insulin binding to
monocytes (Beck-Nielsen et_ a\_ 1978). However, high-fibre, high-
starch, low-fat. diets increased monocyte and adipocyte receptor
number (Ward et al 1982, Pedersen et^ ad 1982b, Hjollund et_ al^ 1983a).
During the menstrual cycle variation in erythrocyte insulin binding
has been reported (Bertoli et al 1980), but the significance of this
is unclear as adipocyte insulin binding remains constant (Pedersen et
al 1982a) as does _tn_ vivo insulin sensitivity (Yki-Jarvinen 1984).
Acute physical exercise has been shown to increase insulin
binding to blood cells from normal subjects (Pedersen et_ al_ 1980).
Pregnancy has been reported to be associated with normal monocyte and
erythrocyte binding (Pedersen et^ ad 1981b, Tsibris et_ ad 1980) but
decreased adipocyte insulin binding (Hjollund et_ ad 1983b).
Conflicting data exist for insulin receptor status in elderly
subjects, both normal (Fink et al 1983) and reduced (Bolinder et al
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1983a) adipocyte insulin binding having been reported.
The results of clinical studies of insulin binding are
summarised in Table 1.1.
CELLULAR INSULIN ACTION
Binding of insulin to its receptor on the cell plasma membrane
is the first step in the cellular action of insulin. The subsequent
events which lead to changes in intracellular enzyme systems are
collectively described as the post-binding steps of insulin action.
The process of insulin internalisation is too slow to account for the
biological effects of the hormone (Denton et al 1981). In addition,
antibodies to the insulin receptor may bring about all the biological
effects of insulin (Kahn et al 1977, LeMarchand-Brustel 1978),
suggesting that the insulin receptor itself carries the information
to induce intracellular changes. The activation of the insulin
receptor itself either by insulin or antibody would appear to be the
event which initiates the sequence of events leading to the observed
intracellular effects.
Plasma membrane transport of glucose was the first site of
insulin action to be recognised (Crofford & Renold 1965). Insulin
causes an increase in the maximum activity of the glucose carrier
without affecting its affinity, but this effect cannot be reproduced
in broken cell preparations (Czech 1980). Insulin appears to bring
about the recruitment of carrier units from an intracellular pool,
associated with the Golgi apparatus, to the cell membrane (Cushman &
Wardzala 1980). In addition to this change, insulin has been shown to
affect the activities of the enzymes responsible for its major
actions on carbohydrate and fat metabolism (Denton £t^ al^ 1981). In
most cases, the effect of insulin upon enzyme is a dephosphorylation
reaction. Changes in cyclic adenosine and guanine monophosphate have
been studied intensively as possible mediators of insulin action
(Hepp et al 1977), but it would appear that the small decrease of the
former and the small increase of the latter are insufficient to
provide a satisfactory mechanism (Kono & Barham 1973, Fain & Butcher
1976). Also, no insulin induced changes in cyclic nucleotide
concentration in muscle cells have been observed (Tarui et al 1976).
Early hopes for ionised calcium (Clausen & Martin 1977), hydrogen
peroxide (Mukerjee & Lynn 1977) and a peptide second messenger
(Larner et_ al_ 1979) have remained unsubstantiated.
The logistics of transmitting a signal from a relatively small
number of plasma membrane insulin receptors to all the cytoplasmic
and mitochondrial enzyme systems of a cell are formidable. To achieve
the required amplification it has been postulated that a membrane
associated protein kinase could phosphorylate many intracellular
protein molecules (Denton et al 1981). This would be similar to the
likely mode of action of epidermal growth factor receptors, binding
to which activates a membrane bound protein kinase which
phosphorylates itself and a range of other proteins (Cohen et al
1980). Recent work on insulin receptor phosphorylation has shown that
the insulin receptor is indeed a protein kinase (Roth & Cassell 1983)
and that insulin can induce receptor autophosphorylation in cell-free
systems (Gazzano et al^ 1983). The immediate substrates for the
receptor protein kinase remain uncertain, as it is able to bring
about phosphorylation of tyrosine and serine residues on all possible
substrates yet tested (DeMeyts 1984).
INSULIN RESISTANCE IN CLINICAL STATES
Insulin resistance may be considered to be present when normal
concentrations of insulin produce a subnormal biological response.
Thus the presence of insulin resistance in vivo is implied either by
the coexistance of a raised plasma insulin concentration and
euglycaemia or hyperglycaemia, or of normal plasma insulin
concentration and hyperglycaemia. Quantification of the degree of
insulin resistance has been attempted by subcutaneous insulin and
oral glucose administration (Himsworth 1935), intravenous insulin
tolerance tests (Beck-Nielsen 1978), combined glucose and insulin
infusions (Harano et_ al_ 1978) and euglycaemic hyperinsulinaemic
clamps (DeFronzo e£ aA 1979). It is apparent that any one of four
distinct biochemical steps could be responsible for cellular insulin
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resistance: binding of insulin to its receptor, initiation of a
transmembrane signal, generation of an intra-cellular signal and
subsequent modification of the transport systems and enzymes that
result in the ultimate biological effects of insulin. At the present
time clinical studies can merely assess two components of insulin
action: the binding reaction in terms of receptor number and affinity
and secondly overall insulin action in terms of maximal insulin-
induced response and sensitivity of the response to insulin. Attempts
have thus been made to categorise insulin resistant states into those
characterised by binding defects alone and those characterised by
intracellular or post-binding defects.
The common clinical states associated with insulin resistance
are obesity (Harrison et_ al 197b, Olefsky 1976), non-insulin
dependent diabetes (Olefsky & Reaven 1977, Beck-Nielsen 1978) and
insulin-dependent diabetes (Harano et_ al^ 1981, DeFronzo e_t al_ 1982).
In obesity, decreased monocyte insulin receptor number has been
demonstrated repeatedly (Archer et al 1973, Bar et al 1976, Beck-
Nielsen 1978), only two studies having found normal monocyte insulin
binding (Misbin e_t a_l 1979 6 1983). Adipocyte insulin receptor number
has been shown to be decreased in obesity by most workers (Kolterman et
al 1980, Pedersen e£ al 1981c, Olefsky 1976) but not all (Amatruda et_
al 1975). The early suggestion that reduced cellular receptor number
explained the insulin resistance of obesity (Olefsky 1976) has been
displaced by the finding of post-binding defects of insulin action
both in adipocytes (Pedersen e_t al 1981c, Ciaraldi e£ ajL^ 1981) and in
vivo (Olefsky £t_ al^ 1982a). It has been postulated that a spectrum of
cellular defects may be responsible for insulin resistance, from those
only involving binding to combined binding and post-binding defects
(Olefsky 1982a).
Receptor defects were inferred as the cause of the insulin
resistance in non-insulin dependent diabetics following blood cell
receptor studies (Olefsky & Reaven 1977, Beck-Nielsen 1978).
Adipocyte insulin binding in non-insulin dependent diabetes has been
observed to be low (Kolterman et a_l 1981, Rizza et_ al_ 1981) or normal
(Bolinder et_ al_ 1982, Lonnroth et_ al 1983a, Kashiwagi e£ al 1983),
but studies of insulin action in adipocytes from non-insulin
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dependent diabetics have consistantiy shown insulin resistance. Both
basal and maximally insulin-stimulated rates of adipocyte glucose
transport have been observed to be subnormal in non-insulin dependent
diabetes (Ciaraldi et al 1982), suggesting the presence of post-
binding defects of insulin action, in insulin-dependent diabetes,
cellular insulin binding defects have been described although intra¬
cellular defects of insulin action appear to be of greater importance
(Pedersen et_ al_ 1982c, Lonnroth et^ al^ 1983b).
Pathogenetic mechanisms for the insulin resistance remain
obscure. In obesity, it has been proposed that consistant overeating
provok.es hyperinsulinaemia which causes binding and post-binding
defects in cellular insulin action (Kahn 1980). Induction of post-
binding defects in adipocytes after six hour insulin infusions in
normal subjects has recently been described (Mandarino et^ al 1984).
The primary defect in the induction of insulin resistance in non-
insulin dependent diabetes has been postulated to be hypersecretion
of insulin, and in insulin-dependent diabetes, peripheral hyper¬
insulinaemia brought about by subcutaneous insulin administration.
Other clinical states including hepatic cirrhosis, thyrotoxicosis and
chronic renal failure have been reported to be associated with
insulin resistance. The cellular basis of the insulin resistance in
these states is uncertain, and factors common to both these disorders
and overt diabetes mellitus have not previously been explored.
AIMS OF TEE PRESENT STUDIES
The present studies were undertaken to examine the pathophysiology
of insulin resistance in disease states characterised by insensitivity
to endogenous or exogenous insulin. In order to assess the utility of
monocyte insulin binding as a tool for the indirect assessment of
insulin receptor status in metabolically relevant tissue, a comparative
study of monocyte and adipocyte insulin binding in normal and disease
states was performed. Using the adipocyte as a model in which insulin
receptor status and cellular insulin sensitivity could be determined
simultaneously, the conditions of hepatic cirrhosis, chronic renal
failure, hyperthyroidism and "brittle" diabetes were investigated.
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Physiological
High sucrose diet
Low calorie diet
Exercise
Pregnancy
Old age
Associated with diabetes
IDD (average control)
IDD (poor control)
IDD (high fibre diet)
NIDD (non-obese)
Glibenclamide therapy
Metformin therapy
Infant of diabetic mother
Associated with other
clinical states
Obesity
Cirrhosis
Chronic renal failure
Cushings syndrome
Acromegaly
Insulinoma
Thyrotoxicosis
CELL TYPE STUDIED
ADIPOCYTE MONOCYTE ERYTHROCYTE
1
T
t
NI
4
N
-I
N
N
N
T
T
*
N
N
N
N
1
T
N
T
N
N
T
1
N
REFERENCES
20
21,23,324
271
150,273,340
33
101,307
213,269,270
277
278
276
191,255,302
32,212
22,151
156,215
247
273
5,81,179,
189,190,211
251,274,356
2,234
31,108,136
129,332
112,231,321
249
240
148
9,334
TABLE 1.1 Results of insulin binding studies in various clinical
states in man. Arrows indicate increased or decreased
maximum specific insulin binding, and N denotes normal
insulin binding.
CHAPTER TWO
CLINICAL AND LABORATORY METHODS
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ADIPOCYTE METHODS
a) Adipose tissue biopsy
Subcutaneous adipose tissue was obtained from the upper lateral
gluteal region between 0800 and 0900 hours after an overnight fast.
Following antiseptic skin preparation, lignocaine (1% without
adrenaline) was infiltrated intradermally to produce an area of
anaesthesia approximately 6 cm by 3 cm. A horizontal incision 4 to 6
cm long was made, the skin was mobilised and a self-retaining
retractor (Weisslander) was applied in order to expose the
subcutaneous adipose tissue. A flat disc of adipose tissue weighing
2-6 grams was then dissected out. The subcutaneous tissue was
approximated using interrupted chromic catgut sutures (2-0) and the
incision was closed using a continuous sub-cuticular Vicryl suture (4-
0). A pressure dressing was left in place for 48 hours. No wound
infection nor other complication was observed following any of the
biopsies. The procedure itself was found to be totally painless, and
the sensations reported over the 24-48 hours following adipose tissue
biopsy varied from no discomfort at all to a moderate ache lasting up
to 36 hours. In no case was sleep disturbed nor analgesia required as
a result of the biopsy.
Subcutaneous adipose tissue obtained at the time of elective
abdominal surgery was used to develop and validate the adipocyte
assays. Samples were taken only from met.abolically normal patients
who were taking no drugs known to interfere with carbohydrate
metabolism. All samples were taken at the start of the surgical
procedure.
b) Adipocyte isolation
The adipose tissue sample was placed immediately in glucose-
saline (glucose 5 mmol/1 and sodium chloride 154 mmol/1) and was
maintained at 37°C. Within 30 minutes the tissue was finely chopped
using scissors and the tissue fragments were thoroughly washed in the
glucose-saline solution. Each gram of tissue was incubated in 2 ml of
collagenase buffer (see Appendix I) for 90 minutes at 37°C in a
shaking water bath (120 cycles per minute) as described by Pedersen
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and colleagues (1981a). The resulting material was passed through a
plastic mesh sieve in order to remove excessive fibrous tissue and
subsequently through two nylon mesh plus cotton gauze filters mounted
in syringe barrels. The cell suspension was then washed three times
in glucose free 5% human serum albumin buffer (Appendix I). The
washing procedure consisted of centrifugation for 20 seconds at 10 g,
aspiration of the infranate using a 10 centimeter 17 gauge needle,
addition of fresh glucose free buffer and resuspension of cells.
After the final wash, the cells were resuspended at an approximate
lipocrit (volume of cells divided by total volume of suspension
x 100) of 40%.
The use of very sharp scissors for chopping the tissue sample
was found to be essential to minimise cell lysis, especially with
adipose tissue samples containing a high proportion of connective
tissue. Initial problems with marked cell lysis were associated with
the presence of detergent traces in the nylon mesh, and thorough pre-
washing of the material in distilled water reduced the extent of
lysis. Preliminary studies established that the intact adipose tissue
sample could remain in the glucose-saline solution at 37°C for 90
minutes without development of cell lysis and without loss of insulin
O
binding activity (0.83 and 0.86 % specific binding per 10 cm cell
membrane after 30 and 90 min respectively). Routinely, the intact
tissue sample remained in the glucose-saline transport medium between
30 and 45 min.
c) Adipocyte quantification
The methods of Pedersen and colleagues (1981a) were adopted for
adipocyte quantification. The cell suspension was repeatedly inverted
to achieve even distribution of cells and a microhaematocrit tube was
rapidly filled by immersion in the suspension. Four such tubes were
separately filled, sealed and centrifuged at 10,000 g for two
minutes. To allow rapid and even filling of the microhaematocrit
tubes it was found necessary to transfer the cell suspension to a
short, wide tube (6 ml volume). Considerable practice was required to
achieve uniform suspension of the cells and thus reproducible
estimations of lipocrit. The volume fraction of cell material was
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measured for each microhaematocrit tube and the mean of the four
determinations was used to calculate the dilution factors necessary
to prepare aliquots of 5% and 40% lipocrit suspension as required.
During the clinical studies, the coefficient of variation of the
lipocrit procedure was found to be 2.5%.
A sample of 4pl of freshly prepared suspension was placed on a
haemocytometer and covered with a plastic cover-slide on which a grid
was marked. The diameters of 160 cells were measured under 200 fold
magnification using a micrometer eyepiece which had previously been
calibrated using a stage graticule. The coefficient of variation of
cell sizing was found to be 2.0%. The cell volume (7ld^/6) and surface
area (77dwere calculated for each individual cell using a computer
programme and the mean of the individual cell volumes and surface
areas were derived. As a standard expression of quantity of
adipocytes, binding and insulin action data was expressed per square
area of ceil membrane, this being calculated from the mean cell
volume, mean cell surface area, and the lipocrit. Adipocytes consist
of a large deposit of lipid with a thin rim of membrane bound
cytoplasm, and hence expression of metabolic events in terms of cell
surface area may be more physiological than in terms of cell number,
especially as mean cell size varies greatly both within one
individual and between individuals (Pedersen et^ ad 1981a).
d) Adipocyte insulin binding
A homogenous preparation of insulin monoiodinated at the A^
position was used for the binding studies in order to avoid
variability in binding secondary to the different properties of the
A^ and A^q labelled isomers (Gliemann e£^ al_ 1979). Insulin binding
to adipocyte sy'was measured by incubating 300 pi adiquots of cell
suspension (5% lipocrit) with 100 pi A./ labelled monoiodoinsulin
un
(final concentration 4-16 pmol/1) and 100 pi buffer or ^labelled
insulin (final concentration 120 - 21,000 pmol/1) in duplicate at
37°C in a HEPES buffer (see Appendix I). The binding was stopped by
adding 10 ml chilled NaCl (154 mmol/1). Silicone oil (1 ml; density
0.97 gram/ml) was layered on the surface and the tubes were spun at
1,000 g for three minutes. The cell pellet was harvested using a pipe
X
(defined as that amount of insulin associated with cells and expressed
in terms of the total amount of tracer insulin present)
30
cleaner as described by Gliemann and Sonne (1978). Initially, very
low specific binding was observed, and examination of the chemical
and physical conditions of the incubations were undertaken.
Crude collagenase preparations from two different sources were
compared by disaggregating portions of the same adipose tissue
sample, and no major differences were found in specific insulin
binding at 15, 45 and 90 min (0.65 vs 0.56, 0.83 vs 0.90, and 0.69 vs
0.74 / per 10 cm^ cell membrane for Worthington and P-L Biochemicals
products respectively). Non-specific binding was similar after use of
each collagenase preparation (1.2 vs 1.3 % of maximum tracer binding
respectively). All subsequent studies were performed using a single
batch of P-L Biochemicals crude collagenase.
The effect of different types of albumin upon measured insulin
binding was examined. Collagenase digestion and washing of the cells
was carried out in human serum albumin, and binding was assessed in
buffers containing either highly purified human serum albumin or
Fraction V bovine serum albumin extensively dialysed and charcoal
treated in the laboratory. Specific insulin binding was higher in the
presence of human serum albumin (0.58 vs 0.41 % per 10 cm cell
membrane) and it was noted that the larger adipocytes appeared to
lyse in the presence of bovine serum albumin (mean cell diameters
after incubations 92 vs 82 p; no difference in the distribution of
smaller cells in the two preparations). Similar results were obtained
when all incubations and washes were performed in human serum albumin
or highly purified bovine serum albumin (Hoechst) (1.64 vs 0.88 %
specific binding per 10 cm^ cell membrane; mean cell diameters 139 vs
91 p respectively). Human serum albumin was used in all buffers in
subsequent assays.
The possibility of cell damage induced by vigorous shaking
during the binding incubation was examined by carrying out parallel
binding studies on cells shaken at 130 cycles per min at maximum
stroke length and on cells shaken twice by hand during the
incubation. No excess cell lysis was noted after vigorous shaking and
maximum specific insulin binding was not reduced (1.08 vs 0.99 % per
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10 cm^ cell membrane with and without vigorous shaking respectively).
Dinonyl phthalate was used to separate the cells from medium in
preliminary binding experiments, but it was found that the cell mass
was more cohesive and easier to harvest when silicone oil was used.
To ensure complete collection of cells through the oil the speed of
centrifugation was increased from 800 to 1,000 g. This caused
breakage of over 50% of the polystyrene tubes used hitherto, and the
problem was circumvented by the use of polypropylene tubes.
During the phase of development of the adipocyte methods, the
observed percentage insulin binding increased steadily, and after
incorporation of all the modifications, steady state binding could be
demonstrated (Figure 2.1). Binding assays were routinely stopped at
60 minutes. Specific binding/was calculated bv subtracting the
•0 unlabelled
binding observed in the presence of 10 pmol/l^insulin rrom the total
binding for each insulin concentration. The non-specific binding
averaged 1.5 _+ 0.2% of cell bound insulin at a tracer concentration
of 16 pmol/1. The intra-assay coefficient of variation of specific
binding at a tracer concentration of 4 pmol/1 was 2.3%. Scatchard
analysis was performed using a computer program which depended upon
non-linear regression for derivation of parameters (Scatchard 1949).
e) Insulin Degradation
Degradation of A^-labelled monoidoinsulin under the conditions
described for insulin binding was assessed after 60 and 120 minutes
by addition of 200 pi of trichloracetic acid (12%) to a 200 pi
aliquot of the incubation medium. The precipitate was separated by
centrifugation at 2,000 g for three minutes and the ratio of ^25j
1 2 S
the supernate to I in the precipitate was determined. Degradation
was assessed in the presence of tracer insulin (16 pmol/1) alone and
in the presence of tracer insulin together with an excess of cold
insulin (10 pmol/1). Degradation assessed by this method reflects
both intracellular and extracellular (medium) degradation. As the
latter is not inhibited by high concentrations of insulin,
consideration of the percentage degradation both in the presence and
absence of unlabelled insulin allows assessment of cell-mediated,
specific insulin degradation. The amount of insulin degraded during a
binding assay averaged 1.4 +_ 0.1% of total radio-labelled insulin and
%
(that is, percentage of tracer insulin associated with receptors
according to the theory expounded on page 15)
hence was not likely to affect measurements of steady state binding.
f) Insulin stimulation of lipogenesis
Triplicate 200 pi aliquots of adipocyte suspension (5% lipocrit)
in a glucose-free HEPES buffer (Appendix 1) were pre-incubated at
37°C for 45 min with or without increasing amounts of insulin. D-
(U-l^C)-glucose (0.4 pCi; final concentration 6 pmol/1) was
added and the incubation was continued without shaking for 90
minutes. The reaction was stopped by adding sulphuric acid (200 pi;
1 mol/1) and the tubes were allowed to stand for 60 minutes before
the total lipid fraction was separated using the procedure of Dole
and Meinertz (1960). The time course of lipogenesis is shown in
Figure 2.2. The amount of D-(U^Zf-C)-glucose incorporated into lipid
for each triplicate set of tubes was calculated and expressed as
pmol glucose incorporated per 90 min per 10 cm^ adipocyte
membrane. The intra-assay coefficients of variation for basal and
maximally insulin stimulated lipogenesis were 7.4 and 4.6 %
respectively.
g) Adipocyte glucose transport
D-(U-1^C)-glucose was used to assess adipocyte glucose transport
(Pedersen & Gliemann 1981, Zeuzem 6 Taylor 1984). Aliquots (40 pi) of
40% adipocyte suspensions in glucose free Hepes buffer were pre-
incubated at 37°C for 45 minutes with or without increasing amounts
of insulin (0 - 18,000 pmol/1 final concentration). D-(U-^C)-glucose
(12 pi; final concentration 20 pmol/1) was added and the contents of
the tube were thoroughly mixed. The incubation period was continued
at 37°C for 20 seconds and was terminated by the addition of 2.5 ml
chilled phloretin solution (0.3 nmol/1 in sodium chloride 154
mmol/1). The cells were separated from extracellular medium within
two minutes by spinning through silicone oil at 2,000 g. The cell
pellet was harvested using a pipe cleaner and was added directly to
scintillation fluid (5 ml). Extracellular trapped radioactivity was
assessed by adding phloretin to triplicate aliquots of cells before
injection of D-(U-^C)-glucose. The radioactivity observed in these
separated pellets was subtracted from all other observations. Basal
glucose transport was assessed in quadruplicate and insulin
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stimulated glucose transport in triplicate for each insulin
concentration. The time course of basal and maximally-insulin
stimulated glucose uptake is shown in Figure 2.2. The intra-assay
coefficients of variation were 9% basally and 7% with maximal insulin
stimulation. Results were expressed as pmoles of glucose transported
per 20 seconds per 10 cm^ cell membrane.
MONOCYTE METHODS
a) Development of methods
A major disadvantage of the established monocyte insulin binding
assay was the need for 160 ml of blood to allow the separation of
sufficient cells to perform one assay. The technique of single bag
plasmapheresis appeared to offer the facility of isolating large
numbers of leucocytes without depletion of red cell mass. The
technique involves venesection of 500 ml of blood directly into a
Fenwal triple pack which is then centrifuged at 1,000 g. The plasma
and subsequently the buffy coat fraction are expressed into separate
integral bags. The red cells and plasma are returned to the
subject. The mean yield of leucocytes was 22.2 +_ 6.4 x lO'' (n=3)
compared with 12.4 +_ 1.9 x 10^ (n=6) using simple centrifugation of
blood. The percentage of monocytes in the leucocyte suspension was
not greatly changed by the procedure (20 + 1.8 vs 23.8 + 1.7 %
respectively). However, the procedure was found to be disliked by all
subjects. Attempts were therefore directed to increasing the yield of
leucocytes from smaller volumes of blood obtained by simple
venesection. The first step of the separation procedure,
centrifugation and harvesting of buffy coat cells, was found to leave
approximately 60 % of leucocytes trapped in the red cell mass.
Dilution of anticoagulated blood with an equal volume of phosphate
buffered saline and centrifugation in 8 universal containers brought
about an increased yield of leucocytes (9.9 +_ 1.1 x lO'' (n=6) vs 12.4
+_ 1.9 x 10? (n=6) from 80 and 150 ml of blood respectively) without
change in the proportion of monocytes present (23.3 + 2.3 vs 23.8 +
1.7 % respectively).
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Monocytes account for over 80 % of the specific insulin binding
of the mixed monocuclear cell population isolated by Ficoll-Hypaque
density gradient centrifugation (Beck-Nielsen et al 1977). To allow
direct measurements upon monocytes, attempts were made to isolate
pure monocyte preparations. Loos and colleagues (1976) reported that
monocytes and lymphocytes could be separated by discontinuous density
gradient centrifugation. Mononuclear cell suspensions were
centrifuged over Ficoll-Hypaque in density layers of 1.055, 1.062 and
1.080 gram/ml. The calculated density of each solution was confirmed
using an Abbey refractometer. The results of the separation of cells
into light (density >1.055<1.062 grams/ml) and heavy (density >1.062
<1.080 grams/ml) cells were assessed by cell counting in a
haemocytometer and non-specific esterase staining for estimation of
the percentage of monocytes present (Horwitz et_ al^ 1977). The yield
of monocytes was low by this procedure although monocyte enrichment
was observed (Table 2.1). Substantial numbers of monocytes were found
in the heavy cell band. Loos and colleagues assessed the separation
of monocytes and lymphocytes using electronic cell sizing and
indirect measurement of phagocytosis and hence may have demonstrated
merely that large mononuclear cells and activated macrophages have a
lower density than small mononuclear cells and quiescent monocytes.
In view of the poor yield and relatively poor separation of
monocytes, the technique was not examined further.
Monocytes may be differentiated from lymphocytes by their
capacity to adhere to inert surfaces (Brodersen & Burns 1973).
Aliquots of mononuclear cell suspensions in Medium 199 with 10 %
foetal calf serum were incubated in plastic Petrie dishes on ice for
60 min. The adherent cells were displaced by pipette aspiration and
expulsion. Less than 10 % of the mononuclear cells were found to
adhere and be displaced by this method, and no non-specific esterase
staining could be demonstrated in the adherent cell population on
three occasions, although the cells appeared to be mainly of monocyte
morphology on phase-contrast microscopy. Further assessment of this
method of monocyte isolation was not undertaken because of the
uncertainty surrounding the effect of the procedure upon the staining
properties of the cells and possible effects of metabolic changes
35
associated with cell attachment upon monocyte insulin binding.
b) Cell isolation
Venous blood samples (80 ml) were obtained from fasting subjects
between 0800 and 0900 hours, were anticoagulated with E.D.T.A. and
were immediately placed on ice. The blood was diluted 1:1 with
phosphate buffered saline (pH 7.4) to maximise the yield of buffy
coat cells obtained by centrifugation at 500 g for five minutes.
Mononuclear cells were isolated by density gradient centrifugation of
the buffy coat cell suspension using Ficoll/Hypaque (density 1.077
gram/ml), and were subsequently washed three times in phosphate
buffered saline. The cells were resuspended in 4 ml of the assay
buffer (see Appendix I). Cell counting and assessment of viability
were carried out in a haemocytometer using Trypan blue as a vital
stain. The coefficient of variation of cell counting was found to be
3.5% and viability was always greater than 98%. The percentage of
monocytes in the mononuclear cell suspension was determined using a
non-specific esterase stain (Horwitz et_ al_ 1977). The accuracy of
this estimation directly affects the accuracy of the assay itself,
observed binding being corrected to be expressed per 10^ monocytes. A
series of preparations were independently assessed by a consultant
haematologist and the Spearman rank correlation coefficient was found
to be 0.78, only 3 of the 19 readings differing by more than 5%. The
mixed mononuclear cell preparation contained 15-65 x 10^ cells per
ml, of which 12-33% were monocytes, 67-88% were lymphocytes and <1%
were polymorphonuclear leucocytes.
c) Monocyte insulin binding
Insulin binding to monocytes was measured at 20°C by incubating
150 pi aliquots of mononuclear cell suspension with 50 pi of A^-
monoiodoinsulin (final concentration 10-40 pmol/1) and 50 pi of
buffer or unlabelled insulin (final concentration 0-1,000 nmol/1) as
described by DeMeyts (1976). The incubation was terminated by the
addition of 1 ml chilled normal saline, centrifugation, washing of
the cell pellet with chilled saline (154 mmo/1) and aspiration of the
supernatant. The cell associated radioactivity was assessed by
cutting off and counting the tip of each microfuge tube. The assay
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was originally carried out in 10 ml tubes and the cell suspensions
were transfered to 3 ml polystyrene tubes for centrifugation, washing
and counting. The polystyrene tubes were found to bind insulin, and
this artefact increased the observed non-specific binding to over
15 %. The non-specific binding was decreased to 4.5 +_ 0.5 % (n=6)
by performing the entire assay in 1.5 ml polypropylene tubes, and the
error inherent in a transfer step was avoided.
The time course of insulin binding is shown in Figure 2.1.
Specific binding was calculated by subtracting the percentage binding
observed in the presence of 10 pmol/1 insulin from the percentage
total binding for each insulin concentration, and was expressed as
A^-monoiodoinsulin was degraded during the assay. The intra-assay
coefficient of variation was 4.2% and the inter-assay coefficient of
variation, as assessed by measuring insulin binding to monocytes from
one individual on seven occasions over a six month period, was 8.4%.
IN VIVO STUDIES
a) Glucose tolerance tests
Glucose (75 grams as 375 ml degassed Lucozade) was administered
orally over a 5 minute period between 0800 and 0900 hours after an
overnight fast. Patients remained sitting throughout the test and no
smoking was permitted. Blood samples were taken via a plastic cannula
inserted into an antecubital fossa vein under local anaesthesia.
b) Euglycaemic hyperinsulinaemic clasps
After an overnight fast, three venous cannulae (Venflon) were
inserted. One cannula, in an antecubital vein, was used for
intermittent blood sampling for hormone and metabolite levels and was
flushed with saline (154 mmol/1) after use. A second cannula,
inserted in a retrograde fashion and more distally on the same arm
was used for continuous sampling by a computer controlled glucose
infusion system (Biostator). Arterialization of venous blood was
achieved using the heated hand technique (Abumrad et_ a_l 1981). All
106 monocytes. Less than 2% of total
*
(that is, percentage of total tracer insulinf which is bound to receptors)
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infusions were administered via the contralateral arm. A period of
one hour was allowed to elapse before starting the infusions in order
to complete calibration of the Biostator and to achieve stability of
the glucose sensor response. An infusion of insulin in polygeline
(Haemaccel) at a rate of 50 mU/kg/h was administered and glucose was
infused at a rate determined by the Biostator in order to maintain
the blood glucose at 0.2 mmol/1 below the fasting level (DeFronzo et
al 1979). The glucose disposal rate from 60 - 120 min was determined
from the total glucose infused during this period.
c) Glucose/insulin Infusion
Glucose/insulin infusions were performed by the method of
Harano (1978) but without somatostatin infusion as this has been
shown not to influence the results (Heine et al 1982). Glucose
(6 mg/kg/min) and insulin (50 mU/kg/h) were infused at constant rates
for 150 minutes and venous samples were taken from the contralateral
arm every 15 minutes for blood glucose, blood metabolites, serum
I.R.I, (immunoreactive insulin) and serum C-peptide estimations.
Steady state blood glucose was calculated as the mean of the observed
concentration between 120 and 150 minutes and the mean coefficient of
variation during this period was 4.0 + 0.6 %.
d) Hormone and metabolite assays
Serum was separated and stored at -20°C. Immunoreactive insulin
(I.R.I.) was assayed by the method of Soeldner & Sloane (1965). The
intra- and inter-assay coefficients of variation were 3.6 and 7.3 X
respectively and proinsulin displayed 50 % cross-reactivity in the
insulin assay. C-peptide was assayed by radio-immunoassay (Heding
1975) and the intra- and inter-assay coefficients of variation were
3.1 and 5.5 % respectively. Proinsulin was assayed by a modification
of the method of Rainbow et al (1979) using flexible microtitre
plates as solid phase and ^^I labelled mouse monoclonal anti-rabbit
immunoglobulin. Proinsulin from human pancreas was extracted and
calibrated for use as previously described (Rainbow et^ al_ 1979).
The specificity of the proinsulin assay was 100 % for circulating
proinsulin (65A^ ancj 32-33 split isomers) and the intra- and
inter-assay coefficients of variation were 5.8 and 10.0 %
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respectively. Blood glucose was measured using a Yellowsprings
analyser within 30 minutes of sampling, delay in analysis having been
shown to be important despite the presence of fluoride oxalate
(Sidebottom £t al^ 1982). Whole blood lactate, glycerol and 3-
hydroxybutyrate were analysed by an enzymatic fluorimetric assay
(Lloyd et_ aT 1978) and the intra- and inter-assay coefficients of
variation for each assay were 2.7 and 4.2 %, 0.7 and 2.2 %, and 8.5
and 10.4 % respectively.
ETHICAL COMMITTEE APPROVAL
The protocol for each study was approved by the Newcastle Health
Authority Ethical Committee. Before participation in any study was
requested, the purpose, nature and potential adverse effects of each
test were fully explained.
PRESENTATION OF DATA
All results are given as mean +_ standard error of the mean.
Statistical analyses were performed using Student's t test (paired or
unpaired as appropriate) and linear correlation when data was
normally distributed. The Mann-Whitney U test and the Spearman rank
correlation were used to analyze skewed data.
Total cell
number xlO^
% monocytes Total monocyte
number xlO^
Initial cell suspension 68.6j^l4.1 25.0+4.7 16.8+4.4
Light cell population 13.2^+5.0 41.0^+1.2 5.3j^2.0
Heavy cell population 23.8+5.5 13.3+1.8 3.1+0.8
TABLE 2.1 Effect of discontinuous density gradient centrifugation
upon monocyte enrichment of mixed mononuclear cell
suspensions. The yield of monocytes in the light cell band
(density >1.055 <1.062 gram/ml) was 29.8 + 4.1 %.
Minutes
FIGURE 2.1 Time course of tracer insulin binding to human
adipocytes at 37°C (top) and to peripheral blood monocytes at
20°C (bottom).
• • Specific insulin binding
o ----- o Non-specific insulin binding
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Seconds
FIGURE 2.2 Time course of adipocyte lipogenesis (top) and
adipocyte glucose transport (bottom),
c* o Non-insulin stimulated
• • Maximally insulin stimulated (14 nmol/1)
CHAPTER THREE
THE RELATIONSHIP BETWEEN ADIPOCYTE AND MONOCYTE INSULIN BINDING
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INTRODUCTION
The major objective of most clinical studies of insulin
receptors has been to examine the role of insulin receptor
abnormalities in the pathogenesis or pathophysiology of an insulin
resistant condition. It is axiomatic that for studies to be relevant
to clinical effects, the receptor status of the major insulin
responsive tissues (liver, muscle and fat) should be examined.
Changes in tissues which do not have a major metabolic response to
insulin would be of interest only if they were to reflect, changes in
the insulin responsive tissues. Shortly after specific binding of
insulin to mononuculear blood cells was first described (Gavin e^ aJ
1972) it was suggested that insulin binding to such cells might
reflect insulin binding to metabolically important cells (Archer et_
al 1973). Since that time it has been widely believed that blood cell
insulin binding mirrors the changes in target organ tissues. A small
number of studies are quoted as supporting this hypothesis. Soli and
colleagues (1973) demonstrated that thymic lymphocytes, adipocytes
and liver membranes from obese mice bound less insulin than
comparable cells or tissue from lean mice. Olefsky (1976) presented
data which suggested a correlation between insulin binding to
monocytes and adipocytes in a mixed group of normal and obese
subjects. However, no evidence for a relationship between insulin
binding to the two cell types in normal subjects was found, and the
relative behaviour of monocytes and adipocytes in clinical states
other than obesity remained uncertain.
In order to clarify the role of monocyte insulin receptor assays
in clinical research, the relationship between insulin binding to
monocytes and insulin binding to adipocytes was examined in normal
subjects and in subjects with disorders of carbohydrate metabolism.
44
SUBJECTS AND PROTOCOL
Binding studies were carried out on thirteen healthy subjects
(aged 28 to 71 years, 101 to 135% ideal body weight) recruited from
the hospital staff, thirteen patients with insulin-dependent diabetes
(16 to 28 years, 95 to 133% I.B.W.), eight thyrotoxic subjects (45 to
67 years, 80 to 125% I.B.W.) and fourteen subjects with
histologically proven cirrhosis (29 to 71 years, 80 to 162% I.B.W.).
Fasting fat biopsies and blood samples were obtained from any one
individual within a three day period, during which time dietary
intake remained constant.
RESULTS
No relationship was found between percentage maximum specific
insulin binding to adipocytes (per 10 cm^ cell membrane) and
percentage maximum specific insulin binding to monocytes (per 10^
monocytes) within the normal group (R = -0.31, p = 0.31), the
cirrhotic group (R = 0.30, p = 0.31), the thyrotoxic group (R = 0.04,
p = 0.99) or the diabetic group (R = -0.23, p = 0.37) (Figure 3.1).
Pooling the data on all 48 individuals failed to demonstrate any
correlation between insulin binding to the two cell types (R = -0.17;
p = 0.22). The lack of correlation was not affected by expressing
adipocyte binding data as maximum specific binding per 30,000 cells.
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FIGURE 3.1 Relationship between percentage maximum specific
o
insulin binding to adipocytes (per 10 cm cell
membrane) and to monocytes (per 10^ cells):
A Normal subjects
B Cirrhotic subjects
C Hyperthyroid subjects
D Insulin-dependent diabetic subjects
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DISCUSSION
The observed lack of correlation between insulin binding to
monocytes and adipocytes might be regarded as surprising in view of
the opinion prevailing in the insulin binding literature. However,
examination of the papers quoted as supporting the concept of
monocytes as reliable indicators of the insulin binding status of
metabolically important cells shows the experimental evidence to be
tenuous. Soil et_ al_ (1973) demonstrated that both thymic lymphocytes
and adipocytes from obese mice bound less insulin than comparable
cells from lean mice. This is often quoted first, as referring to
circulating monocytes (Harrison et^ euI 1976) and second, as showing a
correlation between insulin binding to two cell types rather than a
similar change seen in a specific pathophysiological state. Olefsky
showed that insulin binding to both monocytes and adipocytes tended
to be low in very obese subjects (>130% ideal body weight) but that
there was no correlation between insulin binding to the two cell
types in the normal subjects studied (Olefsky 1976). When the data
from the obese and normal groups were pooled and analysed by linear
regression a statistically significant result was obtained. The
statistical validity of this analysis is questionable, and it is
surprising to find the result (R=0.54) described as an "excellent
correlation" (Bar et al_ 1976).
Although it would appear that insulin binding to fat and blood
cells is decreased in obesity, our data would suggest that binding to
the two different cell types does not necessarily change in the same
direction in all pathological states. We observed low mean insulin
binding to adipocytes but high mean insulin binding to monocytes in
both the insulin-dependent diabetics and the cirrhotic patients.
Pedersen and colleagues also failed to find a correlation between
insulin binding to the two cell types using the same optimised
adipocyte assay but a different monocyte assay in both normal
subjects and insulin dependent diabetics (Pedersen et al 1982a,
Pedersen & Hjollund 1982).
There are several possible reasons for the observed lack of
correlation. It has been assumed in the past that monocytes are a
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homogenous group of cells, although evidence for the existence of
distinct sub-goups has been presented (Nathan et al 1976, Stuart
1977, Braciale e^ aj_ 1982, Katz ejt al_ 1983). It is conceivable that
changes may occur in the sub-group composition of the monocytoid
group of cells in disease states which could of themselves affect the
overall monocyte insulin binding capacity. A second factor which
could account for lack, of correlation between adipocyte and monocyte
insulin binding is the differing environment to which the cell types
are exposed. Adipose tissue is a fixed, peripheral tissue whereas
circulating blood cells pass through the portal circulation and are
thus exposed to pulses of insulin even in the fasting state (Blackard
& Nelson 1970, Lang et_ aA 1979). As insulin is the most potent known
regulator of insulin receptors (Insel et al 1980), it is not
surprising that in insulin dependent diabetes, a condition in which
portal and systemic insulin levels are identical, a dislocation of
any normal relationship between insulin binding to circulating cells
and fixed peripheral tissue cells has been found in the present study
and also by Pedersen & Hjollund (1982). In cirrhosis a similar
mechanism may be operative as hepatic extraction of insulin is
impaired (Johnston et_ aT 1978).
The lack of correlation between insulin binding to monocytes and
adipocytes in normal subjects which has been demonstrated in the
present study and also by Pedersen and colleagues (1982a) is unlikely
to be secondary to either of the two factors discussed above. Other
influences must therefore act differentially upon individual cell
types. Regulation of insulin receptor status may be mediated either
directly upon the cytosolic and plasma membrane receptors, for
example, insulin itself, or indirectly via the nucleus as in the case
of thyroid hormones (Heise et_ al_ 1982). Interpretation of signals by
the nuclei of different cell types could bring about varying effects
upon insulin receptors.
The demonstration of specific insulin receptors on erythrocytes
(Gambhir et al 1977) was also followed by the suggestion that insulin
binding to these cells would reflect insulin binding to the cells of
metabollcally important tissues (Gambhir et al 1978). No convincing
evidence has been provided to support this suggestion and the
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subsequent finding that erythrocyte insulin receptor number depended
heavily upon the age of individual cells (Kosmakos et al 1980, Eng et_
al 1980, Dons et a_l 1981a) did not deter the performance of many
clinical studies (Gambhir et_ al 1980, Bhathena et al^ 1981, Fujita et_
al 1982, Lord ££ a_l 1983). Comparison between monocytes and
erythrocytes show different characteristics of binding to the two
cell types in a variety of conditions (Hjollund et_ a_l 1983c,
Mandarino et_ al_ 1981, Dons et_ al^ 1981b, Spanheimer et_ al^ 1982). This
remains the case even if the effect of erythrocyte age is removed
(Camagna et al 1983). Similarly, the lack of correlation between
insulin binding to erythrocytes and adipocytes (Pedersen et^ al^ 1981a,
Benson et_ al_ 1982, Pedersen 1983) has been adequately revealed.
This is not merely a reflection of differences in assay conditions
for blood cells and adipocytes as performing adipocyte insulin
binding under the conditions necessary for measuring erythrocyte
insulin binding did not improve the correlation (Pedersen & Hjollund
1982).
The accuracy and precision of the binding assays are relevant to
the interpretation of results, as a lack of correlation could merely
reflect upon the assays. The coefficients of variation observed in
the present study compare well with the few published assessments
(Pedersen et_ al_ 1981a, Ward jit^ al 1982). Non-specific binding usually
accounts for 10 to 30% of total binding in both monocyte and
adipocyte assays (Olefsky £t_ al 1974, Beck-Nielsen e_t al^ 1980,
DePirro et al 1981, Nankervis et^ al^ 1982), markedly higher than in
the optimised assays used in this study. The level of specific
binding to adipocytes observed in our normal subjects is not
dissimilar to that recorded by Pedersen, but is higher than that
observed by other workers (Olefsky 1976, Nankervis et_ al 1982)
probably as a result of methodological improvements (Pedersen et al
1981a). Differences exist in the specific insulin binding to
adipocytes from different anatomical sites (Bolinder 1983b) and hence
it is important that adipocytes from only one site are used in
comparative studies.
The relevance of monocyte binding to the insulin receptor status
of the fixed peripheral tissues must be uncertain although there may
be some relationship to overall insulin sensitivity in certain
clinical states (Olefsky & Reaven 1977, Beck-Nielsen et_ aJ 1978). In
cirrhotic subjects a significant correlation between adipocyte (but
not monocyte) insulin binding and both fasting serum insulin and in
vivo insulin sensitivity has been observed in the present studies
(Chapter 4). Insulin sensitivity measured i_n vivo is largely
determined by muscle glucose disposal (DeFronzo et_ aul 1981a) and
therefore these findings suggest that the insulin sensitivity of
muscle corresponds with adipocyte insulin binding at least in
cirrhotic subjects. The two major insulin sensitive peripheral
tissues, muscle and fat, are exposed to identical controlling
influences, although it may not be assumed that adipocytes reflect
the insulin binding status of myocytes or indeed hepatocytes.
Examination of adipocyte insulin binding does provide information
about an insulin sensitive tissue which may be examined in the light
of in vitro studies of insulin action (Pedersen et_ al_ 1981c & 1982a,
Pedersen & Hjollund 1982).
It remains possible that sequential studies of monocyte insulin
binding in groups of individuals could reflect the direction of any
change in receptor status in other tissues. This hypothesis has yet
to be proven in man and preliminary results are not supportive
(Mandarino et al 1984).
CHAPTER FOUR
HEPATIC CIRRHOSIS
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INTRODUCTION
The association between chronic liver disease and impaired
glucose tolerance has long been recognised (Naunyn 1906, Rankin et_ aT
1953, Megyesi et_ al^ 1967). Naunyn (1906) hypothesized that pancreatic
insulin secretion was not subnormal, some effect of the liver damage
itself being responsible for the impairment of glucose tolerance.
This was supported by observation of elevated serum levels of
immunoreactive insulin in chronic liver disease of any aetiology
(Megyesi et al 1967, Johnston et_ al^ 1982, Ghanem et_ al^ 1973) and by
the finding of more marked hyperinsulinaemia in subjects with more
severe impairment of glucose tolerance (Toccafondi et al 1977).
Coexistence of carbohydrate intolerance and hyperinsulinaemia in
chronic liver disease suggests that insulin action is impaired. This
has been confirmed by intravenous insulin tolerance tests (Collins et_
al 1970, West et_ al_ 197 5), although precise quantitation of insulin
resistance by this technique is complicated by the lack of steady
state conditions and variability of the counter-regulatory hormone
response. The pathogenesis of the insulin resistance could involve
circulating antagonists of insulin action or defects in the tissue
response to insulin. Circulating levels of the insulin counter-
regulatory hormones have been intensively investigated. Basal growth
hormone levels have been found to be elevated in most (Conn &
Daughaday 1970, Muggeo et al^ 1979, Borzio et_ al^ 1981) but not all
(Owens al_ 1973, Kasperska-Czyzykowa & Rogala 1978) studies of
subjects with established cirrhosis. However, no correlation between
serum growth hormone levels and the severity of glucose intolerance
has been observed (Collins et ai 1970, Leatherdale et_ aj^ 1980) and
insulin resistance has been demonstrated in a group of cirrhotics
with normal serum growth hormone levels (West e£ a\_ 1975). Although
elevation of serum growth hormone within physiological limits may
induce a degree of insulin resistance (Rizza e£ al^ 1983), such an
effect cannot be assumed in cirrhotic subjects as the sensitivity to
such a change may not be normal. Basal hyperglucagonaemia has
frequently been reported in cirrhotic subjects (Sherwin et al 1978,
Greco et^ aJ 1979, Dudley et^ al_ 1979, McDonald et al 1979) and
immunoreactive glucagon has been shown to be the biologically active,
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pancreatic form of glucagon (molecular weight 35,000) (McDonald et^ al_
1979, Dudley et_ al_ 1979). The sensitivity of the plasma cyclic A.M.P.
response to exogenous glucagon is normal in cirrhotic subjects
(Strange et^ al^ 1977, Radziuk et^ ad 1977). However the degree of
hyperglucagonaemia has been reported to correlate with the degree of
portosystemic shunting rather than hepatocellular function (Dudley et_
al 1979, Sherwin et al 1978) and no correlation of serum
immunoreactive glucagon levels and glucose intolerance could be
demonstrated (Riggio et^ ad 1982). Morning serum Cortisol levels have
been reported to be normal in cirrhotic subjects (Riggio et_ al^ 1982,
Johnston et_ al^ 1982) but the diurnal pattern is disturbed, evening
serum free Cortisol levels being elevated (Johnston et al 1982). It
would appear unlikely that the counter-regulatory hormones,
individually or in concert (Riggio et al 1982) could play a major
role in the insulin resistance of chronic liver disease.
Circulating non-esterified fatty acid levels are raised in
cirrhosis (Leatherdale e^ al^ 1980, Riggio et ad 1982, Owen et_ ad
1981) and this could decrease insulin mediated glucose utilisation by
muscle (Randle et al 1963). Although a correlation between non-
esterified fatty acid levels and glucose intolerance has been
reported (Riggio et_ al_ 1982), the possibility that this is a
secondary effect of the insulin resistance cannot be excluded.
The in vivo resistance to insulin action could be located either
in the liver or in the peripheral tissues, muscle and fat. Direct
study of the forearm tissues in cirrhotic man has demonstrated
peripheral tissue resistance to insulin-mediated glucose uptake,
similar rates of glucose uptake as in control subjects being observed
despite higher serum insulin levels (Leatherdale et_ ad 1980). If the
insulin resistance represents a cellular defect rather than an effect
of circulating factors, it could result from defects at any level
from the initial event of hormone-receptor binding to the activation
of the glucose transport system and the enzymes responsible for
glucose metabolism. Isolated adipocytes were studied in order to
localise any such defects to either receptor or post-binding steps of
insulin action. In addition, the response to an oral glucose load was
assessed and in vivo insulin sensitivity of glucose metabolism was
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measured to allow comparison between the degree of in vivo
abnormalities and any abnormality found at the cellular level.
SUBJECTS AND PROTOCOL
Sixteen patients with stable biopsy-proven cirrhosis who did not
have clinical signs of porto-systemic shunting, ascites or
encephalopathy were studied. No selection criteria concerning
aetiology of cirrhosis were applied, and the group comprised six
patients with alcholic cirrhosis, six patients with primary biliary
cirrhosis (P.B.C.) and four patients with cryptogenic cirrhosis. All
subjects were taking an adequate diet (minimum 200 grams of
carbohydrate daily) and were ambulant. Two patients were receiving
cholestyramine, two penicillamine, one cimetidine, four frusemide and
four spironolactone. No drugs were taken on the morning of a test
day. Eleven control subjects who had normal liver function tests,
were taking no drugs and had no evidence of any metabolic disorder
were also studied. The clinical and biochemical details of the
patient and control group are given in Table 4.1 and those of each of
the aetiological sub-groups of the cirrhotic group are given in Table
4.2.
Each subject was studied on three separate days. On the first
day, blood was taken for monocyte studies and a glucose tolerance
test was carried out. An adipose tissue biopsy was taken on the
second day and in vivo insulin sensitivity was assessed on the third
day. Insulin sensitivity was measured by the euglycaemic clamp
technique in the first eight cirrhotic subjects and by the glucose/
insulin infusion technique in all subsequent subjects.
RESULTS
a) Glucose Tolerance Tests
Mean fasting blood glucose was similar in the cirrhotic and
control group (4.2 + 0.19 and 4.1 +_ 0.14 mmol/1 respectively) (Figure
4.1). After the glucose load, mean blood glucose levels were higher
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in the cirrhotic group becoming significantly different from the
control group within 45 minutes and remaining elevated thereafter
(Figure 4.1). Nine of the group of 16 cirrhotics had impaired glucose
tolerance as defined by the WHO criteria (WHO 1980). Mean fasting
serum I.R.I, was higher in the cirrhotic group (12.1 + 1.4 vs 7.0 _+
1.7 mU/1; p < 0.01) as was the peak I.R.I. (85.8 +_ 7.5 vs 57.0 + 10.5
mU/1; p < 0.05). Values were also significantly higher at 90, 120 and
150 min. Mean fasting serum proinsulin was grossly elevated in the
cirrhotic group (43.2 _+ 5.8 vs 17.2 + 2.7 pmol/1) and remained
elevated throughout the test (Figure 4.2). As proinsulin exhibits 50%
cross-reactivity with insulin in the insulin radioimmunoassay used, a
correction of the observed serum I.R.I, values was calculated for the
effect of the presence of excess proinsulin. Although this reduced
the magnitude of the difference between the cirrhotic and control
groups (fasting: 9.0 +_ 1.5 vs 5.7 +_ 1.5 mU/1; peak: 71 8.1 vs 49.0
+_ 9.2 mU/1) (Figure 4.3) some cirrhotic patients remained markedly
hyperinsulinaemic. Mean fasting C-peptide was higher in the cirrhotic
group (0.51 +_ 0.04 vs 0.34 +_ 0.03 nmol/1; p < 0.05) but the C-peptide
response to oral glucose appeared blunted and delayed. The mean
incremental C-peptide responses did not differ significantly (0.86 +_
0.11 vs 1.02 + 0.13 nmol/1 respectively).
Mean fasting and peak blood glucose levels were similar in the
alcoholic, P.B.C. and cryptogenic groups (Table 4.3). Mean peak
blood glucose levels (9.8 +_ 0.7, 10.3 _+ 1.7 and 10.9 _+ 0.8 mmol/1
respectively; N.S.) were observed at 60 minutes in each group. Mean
blood glucose fell more quickly in the P.B.C. group: 6.0 + 0.8 mmol/1
at 120 minutes compared with 9.2 + 1.6 mmol/1 for the alcoholic group
(p < 0.05) and 8.9 + 1.5 mmol/1 for the cryptogenic group (p =
0.057). Mean fasting serum I.R.I, was lower in both the P.B.C. (10.0
1.0 mU/1) and the cryptogenic group (7.9 +_ 1.2 mU/1) than in the
alcoholic group (16.4 +_ 1.3 mU/1; p < 0.05) (Table 4.3).
b) Euglycaemic clamps
Euglycaemic hyperinsulinaemic clamps were performed on the first
eight cirrhotic subjects studied (mean age 52.3 + 5.3 years; 103 + 8%
ideal body weight; four male/four female) and on the first six
control subjects studied (mean age 44.8 + 0.2 years; 112 + 5% I.B.W.;
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three male/three female). The cirrhotic subjects demonstrated marked
insulin resistance, the mean rate of glucose disposal being 3.4 + 0.5
mg/kg/min compared with 8.3 + 0.9 mg/kg/min for the controls
(p < 0.001). The mean steady state serum I.R.I, was 45.4 +_ 3.8 vs
40.3 +_ 2.4 mU/1 and mean steady state blood glucose was 4.4 +_ 0.1 vs
4.3 +_ 0.1 mmol/1 for the cirrhotics and controls respectively. The
mean fasting blood glucose levels were 4.5 +_ 0.1 and 4.3 +_ 0.1
mmol/1, and the coefficients of variation of clamp blood glucose were
3.1 + 0.2% and 4.8 + 0.3% respectively. Mean glucose disposal rates
during the euglycaemic clamp were 4.4 + 0.9 mg/kg/min for the P.B.C.
group (n=4) and 2.5 + 0.03 mg/kg/min for the alcoholic and
cryptogenic subjects together (n = 4; p = 0.09).
c) Glucose/insulin infusions
The results of the glucose/insulin infusions which were
performed on the last 9 cirrhotic subjects and 8 of the control
subjects are shown in Figure 4.4. Mean steady state blood glucose
levels were highly significantly different (8.3 + 1.0 vs 2.7 + 0.2
mmol/1 at 120 min; p < 0.001). Steady state serum I.R.I, was markedly
higher in the cirrhotic group than in the normal group (65.2 + 6.5 vs
42.8 3.8 mU/1 at 120 minutes; p < 0.05). Insulin secretion was
suppressed in the control group, C-peptide levels falling steadily
over the last 90 minute of the infusion, but in the cirrhotic group
C-peptide levels rose to a peak level at 120 minutes (1.14 + 0.19 vs
0.32 +_ 0.07 nmol/1, p < 0.01) (Figure 4.4). The P.B.C. group were
less insulin resistant than either the alcoholic or the cryptogenic
groups. Mean steady state blood glucose was 5.3 F_ 0.73 mmol/1 for
the P.B.C. group and 10.6 +_ 1.1 mmol/1 for the combined alcoholic and
cryptogenic groups (p < 0.05).
d) Blood intermediary metabolite levels
Fasting blood glycerol was 0.08 ^F 0.01 mmol/1 for the cirrhotic
group and 0.04 +_ 0.01 mmol/1 for the control group (p < 0.01). There
were no significant differences between the cirrhotic and control
groups in the fasting levels of blood lactate (0.84 +_ 0.09 vs 0.73 +
0.07 mmol/1 respectively) or 3-hydroxybutyrate (0.099 +_ 0.023 vs
0.056 +_ 0.024 mmol/1 respectively). During the steady state period of
the glucose/insulin infusions there were no differences between the
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cirrhotic and control group in the levels of blood lactate (1.13
0.11 vs 1.07 +_ 0.09 mmol/1), 3-hydroxybutyrate (0.012 _+ 0.003 vs
0.008 +_ 0.001 mmol/1) nor glycerol (0.03 +_ 0.01 vs 0.03 _+ 0.01
mmol/1).
e) Monocyte insulin binding
There was no significant difference between the mean percentage
insulin binding to monocytes from cirrhotic and control subjects
(2.15 + 0.16 vs 1.92 + 0.31% per 106 monocytes respectively) (Figure
4.5). Half-maximum displacement of tracer was observed at 125 + 13
and 132 + 10 pmol/1 respectively. There were no significant
differences in maximum insulin binding between each of the cirrhotic
sub-groups (2.02 _+ 0.2%, 2.24 +_ 0.33 and 1.90 +_ 0.34% for alcoholic,
P.B.C. and cryptogenic groups respectively).
f) Adipocyte insulin binding
The adipocyte insulin binding displacement curves are shown in
Figure 4.6. The adipocytes from the cirrhotic patients bound
significantly less insulin at tracer insulin concentrations (2.21 +
0.12 vs 2.64 + 0.13 % per 10 cm^ cell membrane; p < 0.05). Half-
maximum displacement of bound insulin occurred at 139 _+ 11 pmol/1 for
the control group and 172 + 17 pmol/1 for the cirrhotic group (p >
0.1). Scatchard analysis suggested that the difference in maximum
binding was largely a result of decreased receptor number on the
adipocytes from cirrhotic patients (53.4 _+ 4.9 vs 63.4 _+ 4.8
receptors per pm^ membrane) (Figure 4.6). Maximum binding to
adipocytes from the P.B.C. and cryptogenic groups was similar (2.44 +
0.17 and 2.40 +_ 0.10 %). Adipocytes from the alcoholic group bound
significantly less insulin (1.89 + 0.20 % per 10 cm cell membrane)
than either the non-alcoholic cirrhotics (p < 0.05) or the normal
subjects (p < 0.001). There was no significant difference between the
insulin concentrations required for half-maximum displacement of
tracer insulin for the alcoholic, P.B.C. and cryptogenic groups (178
+ 29, 143 +_ 15 and 208 +_ 45 pmol/1 respectively).
g) In vitro lipogenesis
The basal rate of lipogenesis was not significantly different in
adipocytes from cirrhotic and control subjects, but the mean maximum
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rate of lipogenesis was greater for the cirrhotic group (p < 0.05)
(Figure 4.7). However, Figure 4.8 shows that the cirrhotic patients
do not form a homogenous group with respect to absolute rates of
adipocyte lipogenesis. Adipocytes from the cryptogenic group achieved
significantly higher rates of lipogenesis than those from the
alcoholic group at all insulin concentrations and than those from the
P.B.C. group at all insulin concentrations above 135 pmol/1. The
P.B.C. group achieved significantly higher rates of lipogenesis than
the alcoholic group at all insulin concentrations above 27 pmol/1.
There were no significant differences between the control group and
any sub-group in basal rates of lipogenesis, but both the P.B.C. and
cryptogenic groups achieved higher maximal rates of lipogenesis
(p < 0'.05 and p < 0.01 respectively). Adipocytes from cirrhotic
subjects were relatively resistant to insulin stimulation (half-
maximum stimulation at 60.0 +_ 8.0 pmol/1 for cirrhotics and 21.8 +
3.3 pmol/1 for controls; p < 0.001). The half-maximal values for the
alcoholic, P.B.C. and cryptogenic sub-groups were 46 + 8, 66 + 15
and 69 _+ 19 pmol/1 respectively (p < 0.05, p < 0.01 and p < 0.01
respectively compared with control group).
h) Relationship between cellular insulin binding and in vivo insulin
sensitivity
There was a direct correlation between specific insulin binding
to adipocytes and in vivo insulin sensitivity as determined by the
glucose/insulin infusion technique both for the cirrhotic group
(Rg = 0.63; p < 0.05) and for the cirrhotic and control subjects
together (Rg = 0.74; p < 0.01) (Figure 4.9). Similarly there was a
negative correlation between fasting serum I.R.I. and specific
insulin binding to adipocytes (Figure 4.9) both for the cirrhotic
group (Rs = 0.54; p < 0.05) and for the whole group (Rg = 0.43; p <
0.05). The cirrhotic group were relatively homogenous with respect
to euglycaemic clamp data, and no correlation with adipocyte insulin
binding could be demonstrated. Similarly, there was no correlation
within the control group between the relatively narrow range of
normal steady state blood glucose levels (1.8 to 3.5 mmol/1) and
adipocyte specific insulin binding. Monocyte insulin binding
correlated neither with in vivo insulin sensitivity nor with fasting
serum I.R.I. (Figure 4.10).
CIRRHOTICS
n = 16
Age (years) 53+3
Male/female ratio 9/7
% I.B.W. 108 + 6
Adipocyte diameter (p) 102 + 5
Diet - grams
carbohydrate/day 275 +_ 26
Diet - kcal/day 2217 +^ 168
Bilirubin (pmol/1) 38 +_ 12
A.S.T. (1U/1) 81 + 11
Alkaline phosphatase
(IU/1) 400 + 86
Albumin (grams/1) 36.7 + 1.4
Prothrombin ratio 1.1 + 0.03
CONTROLS
n = 11
42 + 4
6/5
111 + 4
101 + 6
261 + 32
2400 + 149
8 ± 1
25 + 6
61 + 12
44.0 + 1.2
TABLE 4.1 Clinical and metabolic details of the cirrhotic and
control groups.
59
ALCOHOLIC P.B.C.
n = 6 n = 6
CRYPTOGENIC
n = 4
Age 49+4
Male/female ratio 6/0
% I.B.W. 117 + 7
Adipocyte diameter (p) 114+^ 7
Diet - grams carbohydrate
/day 291 ^+ 17
Diet - kcal/day 2329 +_ 129
Bilirubin (pmol/1) 19+_ 5
A.S.T. (IU/1) 74 + 11
Alkaline phosphatase
(IU/1) 160 + 39
Albumin (grams/1) 39.2 +_ 2.0
Prothrombin ratio 1.1 + 0.8
61 + 5
0/6
90+3
95 + 7
227 + 35
1995 + 174
*61 + 31
88 + 22
789 + 99
36.8 + 1.9
1.0 + 0.02
49 + 8
3/1
121 + 15
96 + 14
318 + 38
2480 + 219
32 + 7
80 + 30
179 + 34
32.8 + 3.1
1.3 + 0.03
TABLE 4.2 Clinical and metabolic features of the subgroups of
cirrhotic subjects. *The P.B.C. group included the only
jaundiced patient of this series (serum bilirubin 210 pmol/1).
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ALCOHOLIC P.B.C. CRYPTOGENIC CONTROLS
GLUCOSE
Fasting #4.6+0.3 4.1+0.1 3.8+0.2 4.1+0.1
60 min #9.8+0.7 #10.3+1.7 #10.9+0.8 *5.5+0.4
120 min #9.2+1.6 #*6.0+0.8 #8.9+1.5 *3.9+0.4
INSULIN
Fasting #16.4+1.3 *10.0+1.01 *7.9+1.2 *7.0+1.7
60 min #95.5+14.0 80.0+12.7 *52.5+9.4 *55.7+7.5
120 min #84.8+13.2 #*42.2+9.6 #59.6+6.8 *18.2+2.9
TABLE 4.3 Blood glucose (mmol/1) and serum I.R.I. (mU/1) during oral
glucose tolerance test in the cirrhotic subgroups.
* p< 0.05 compared with alcoholic group.
# p< 0.05 compared with control group.
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Glucose
mmol/l
IRI
mU/l
C-peptide
nmol/l
0 30 60 90 120 150
Minutes
FIGURE 4.1 Mean blood glucose, serum l.R.I. and serum C-peptide
response to 75 grams oral glucose.
Cirrhotic group (•——•), control group (o——o).
* p< 0.05; ** p< 0.01; *** p< 0.005
62
FIGURE 4.2 Mean serum proinsulin levels during oral glucose
tolerance test.
Cirrhotic group (• • ), control group (o——o).
p< 0.01 at all time points.
FIGURE 4.3 Mean serum immunoreactive insulin levels (panel A) and
mean serum insulin levels corrected for proinsulin
cross-reactivity (panel B).
Cirrhotic group n=16 (• • ), control group n=6 (o o).
* p< 0.01
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FIGURE 4.4 Mean blood glucose, serum I.R.I, and serum
C-peptide changes during glucose/insulin infusion.
Cirrhotic group n = 9 (• •), control group n=8 (o o)
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FIGURE 4.5 Specific insulin binding to monocytes.
Cirrhotic group n = 14 (• • ).
Control group n = 11 (o- o).
Insulin concentration (mol/l)
FIGURE 4.6 Specific insulin binding to adipocytes displayed as
binding displacement curves (top) and Scatchard plots
(bottom).
Cirrhotic group n = 16 (•- •)•
Control group n = 11 (o o).
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FIGURE 4.7 Insulin stimulation of lipogenesis in adipocytes
shown as absolute rates and as percentage stimulation.
Cirrhotic group n = 16 (• • ).
Control group n = 11 (o o).
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FIGURE 4.8 Insulin stimulation of lipogenesis in adipocytes from
patients with cryptogenic (n = 4), primary biliary (n = 6)
and alcoholic (n = 6) cirrhosis.
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FIGURE 4.9 Relationship between adipocyte insulin binding and
fasting serum insulin (top: Rg = 0.54, p <0.05 for cirrhotics)
and steady state blood glucose (bottom: Rg = 0.63, p < 0.05
for cirrhotics).
Cirrhotic (•) and control (x) subjects.
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FIGURE 4.10 Relationship between monocyte insulin binding and
fasting serum insulin (top: Rg = 0.32 for cirrhotics)
and steady state blood glucose (bottom: Rs = 0.63 for
cirrhotics).
Cirrhotic (•) and control (x) subjects.
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DISCUSSION
The oral glucose tolerance tests in the cirrhotic subjects
demonstrated impairment of glucose tolerance, fasting
hyperinsulinaemia and delayed, exaggerated peak insulin responses
which have been previously demonstrated (Collins et^ aT 1980, Riggio
et al 1982, Johnston et_ a\_ 1977). The cause of the hyperinsulinaemia
has been reported to be a result of impaired insulin degradation by
some workers (Riggio et a_l 1982) and hypersecretion of insulin by
others (Megyesi et_ al^ 1967, Johnston et_ al_ 1977). Our observation of
raised fasting C-peptide levels, but lesser change in serum C-peptide
after oral glucose in the cirrhotic subjects would suggest that the
fasting hyperinsulinaemia was secondary to an increased basal insulin
secretion rate, but that impaired hepatic extraction or degradation
allowed post-prandial hyperinsulinaemia. Any such impaired insulin
handling could be a result of porto-systemic shunting or intrinsic
hepatic abnormalities. As post-prandial hyperinsulinaemia is not
observed in patients with portal vein thrombosis and normal liver
function (Johnston et^ al_ 1978), the latter possibilty appears to be
more likely. Previous studies have attempted to explain the
abnormalities of insulin secretion in cirrhosis on the basis of a
single defect (Megyesi et al 1967, Johnston et^ al^ 1977, Riggio et al
1982). The possibility has not been considered to date of both basal
hypersecretion and impaired hepatic degradation, the relative
contributions of each to overall serum insulin levels varying with
insulin secretion rate. The abnormal temporal pattern of C-peptide
and therefore of insulin secretion must be considered in relation to
possible abnormal absorption of the glucose load in cirrhotic
subjects.
A further point in the consideration of hyperinsulinaemia is the
crossreactivity of insulin and proinsulin in the radioimmunoassays.
Previously it has been assumed that I.R.I, directly reflected
biologically active insulin in cirrhotic subjects. Correction for
this artefact of measurement (Figure 4.3) reveals that although
hyperinsulinaemia is present in some patients, the degree of
abnormality is less than has been reported. Recently,
hyperproinsulinaemia in cirrhosis has been confirmed by a group using
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a different proinsulin assay (Kasperska-Czyzyzkowa et al 1983). The
hyperproinsulinaemia could result from diminished degradation of
proinsulin, but at least 50 % of proinsulin is cleared via the
kidneys (Katz & Rubenstein 1973) and abnormal secretion of proinsulin
cannot be excluded at present.
Nine of the group of 16 cirrhotic subjects had impaired glucose
tolerance as defined by the WHO criteria (1980). The degree of
impairment of glucose tolerance bore no relationship to adipocyte
insulin binding or insulin sensitivity nor to measured insulin
sensitivity in vivo. The latter assessment relates almost entirely to
the peripheral tissues (DeFronzo et_ al^ 1983). It is thus likely that
peripheral tissue insulin resistance is but one factor involved in
the pathogenesis of impaired glucose tolerance. As approximately 50%
of an oral glucose load is taken up by the liver (Waldhausl et_ al_
1983) it is apparent that reduction of the functional parenchymal
mass or a reduction in sensitivity to insulin stimulated glucose
metabolism or storage may be very significant in the pathogenesis of
impaired glucose tolerance in cirrhosis.
The existence of resistance to insulin action in cirrhosis has
long been postulated on the basis of indirect studies (Collins et_ a_l
1970, Johnston et al 1977). Human forearm studies showed that glucose
uptake was normal in the presence of hyperinsulinaemia, suggesting
peripheral tissue insulin resistance (Leatherdale et_ al 1980).
Recent studies using the euglycaemic hyperinsulinaemic clamp
technique have reported marked peripheral insulin resistance in
cirrhosis (Iversen et al 1984, Vannini et_ al^ 1984). Similar
observations were made in the present study. The low rates of glucose
disposal recorded in the cirrhotic subjects did not allow confident
ranking of the subjects with respect to insulin resistance. In order
to achieve better separation between the more severe degrees of
insulin resistance, the glucose/insulin infusion technique (Harano et_
al 1978, Heine et al 1982) was used in the second part of the study.
The marked resistance to the action of insulin in promoting glucose
disposal was fully displayed using this technique, and the apparent
effect of the hyperglycaemia of the cirrhotic subjects in stimulating
a degree of endogenous insulin secretion did not mask the insulin
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resistance. Both the euglycaemic clamp and the glucose/insulin
infusion techniques measure predominantly peripheral tissue glucose
disposal, hepatic glucose production being effectively suppressed at
the insulin infusion rate used (50 mU/kg/h) (DeFronzo et al 1983).
Hepatic glucose output was not assessed in this study, and it must be
considered that the peripheral tissue glucose disposal in the
cirrhotic subjects might have been underestimated if hepatic glucose
output was not adequately suppressed. However, even if hepatic
glucose output was only 50% suppressed this would only increase the
overall glucose disposal rate by approximately 1 mg/kg/min.
Assessment of basal hepatic glucose output by both catheterisation
and isotope techniques has suggested decreased hepatic glucose
release in cirrhosis (Owen e£ ai^ 1976, Perez et_ al^ 1978). It would
thus appear unlikely that the i_n vivo insulin sensitivity in
cirrhosis has been seriously underestimated in the present study. The
finding of marked peripheral insulin resistance corroborates the in
vivo observation on forearm glucose metabolism (Leatherdale et al
1980) but leaves open the question of its pathophysiological basis.
Adipocyte insulin binding was found to be reduced in the
cirrhotic group, and the reduction correlated both with the elevation
of fasting serum I.R.I, levels and the decreased in vivo insulin
sensitivity. In the only other study of adipocyte insulin binding in
cirrhosis, no significant decrease in binding was observed (Harewood
et al 1982). In that study, adipocyte binding was performed on only
six subjects with cirrhosis of unstated aetiology. The binding data
were expressed per cell number and this could have resulted in
underestimation of the true insulin binding in the cirrhotic group as
the cells of the cirrhotics (predominantly male) were significantly
smaller than those of the controls (predominantly female). The assay
used by Harewood and colleagues was associated with non-specific
binding of insulin of 27.7%, and this analytical difficulty may have
contributed to the large standard errors of each group mean. Finally,
the subjects studied were all undergoing porto-systemic shunt
operations. In contrast, all the patients reported in the present
study had no clinical evidence of portal hypertension and were in a
stable condition.
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Several previous studies have examined insulin binding to non-
target organ cells in cirrhosis. In a group of alcoholic cirrhotics,
monocyte insulin binding was found to be reduced (Greco et_ al 1980).
Blei and co-workers observed no reduction in monocyte insulin binding
in a group of 16 patients with cirrhosis of varying aetiology but
found that the five hyperinsulinaemic cirrhotics had reduced monocyte
insulin binding (Blei ££ a^L 1982). In a group of Japanese patients
with unspecified liver disease, monocyte insulin binding was found to
be reduced in direct proportion to the severity of impairment of
glucose tolerance (Kanatsuna et_ al_ 1981), whereas in a large group of
Caucasian cirrhotics, monocyte insulin binding was normal in those
subjects with impaired glucose tolerance and was reduced only in
those subjects with normal glucose tolerance (Piniewski e_t al 1984).
These conflicting results may reflect alterations in mononuclear cell
subpopulations in different types of cirrhosis, or indeed any
alterations in the monocyte staining properties as this would
directly affect the results derived from the study of mixed
mononuclear cell preparations. Lack of correlation between monocyte
and adipocyte binding has previously been reported in normal subjects
(Olefsky 1976) and insulin dependent diabetics (Pedersen & Hjollund
1982). The possible pitfalls in deriving physiological significance
from results of monocyte binding studies necessarily performed at
20° C and pH 8.0 are evident, and these could account at least in
part for the lack of correlation with the adipocyte binding studies
as discussed in Chapter 3.
The finding of reduced adipocyte insulin receptor number is of
interest, but the relationship of the hyperinsulinaemia to receptor
downregulation and to the insulin resistance is unclear. It is
possible that the receptor downregulation could be a secondary effect
of the hyperinsulinaemia, the latter being both a response to post-
receptor insulin resistance and a manifestation of impaired insulin
degradation. The degree of resistance to adipocyte insulin
stimulation of lipogenesis did not differ significantly between the
three cirrhotic sub-groups although the adipocytes from the alcoholic
subjects required a slightly lower mean insulin concentration for
half-maximum stimulation. However, only the alcoholic sub-group
displayed marked reduction of insulin binding to adipocytes. The
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observed cellular insulin resistance did not relate to insulin
receptor status. The decrease in sensitivity is in agreement with the
data of Harewood et al (1982) which also reflected the greater
maximum capacity of adipocytes from cirrhotic subjects to synthesise
lipid in vitro. Caro and Ainatruda (1980) have demonstrated that the
process of downregulation involves post-binding pathways. It may be
argued that the adipocytes from the non-alcoholic cirrhotic subjects
had a greater post-binding defect and thus displayed slightly greater
insulin resistance and failure to downregulate. Interpretation of the
insulin sensitivity data is complicated by the different degree of
reponsiveness of each group. Although it has been postulated that
cellular hormone sensitivity (as represented by hormone concentration
required for half-maximal stimulation) and cellular responsiveness
(as represented by the increment over the basal metabolic state
achieved by maximum hormone stimulation) are separate and independent
parameters (Kahn 1978), uncertainty must exist when comparing the
sensitivity of different cell populations with disparate
responsiveness. Reduction in responsiveness is conventionally taken
to indicate the presence of a post-binding defect and reduction in
sensitivity to indicate the presence of a binding defect. These
theoretical distinctions are not absolute (Kahn 1978). At the present
time, the adipocyte insulin receptor downregulation of the alcoholic
group may be more simply accounted for by the more marked
hyperinsulinaemia in this group. An intracellular defect of insulin
action appeared to be prominent in the sub-group with the least in
vivo insulin resistance (P.B.C.), the iri vitro adipocyte insulin
resistance being associated with near normal insulin binding.
Evidence for an important in vivo post-binding defect is provided by
a dose response euglycaemic clamp study which demonstrated 30%
reduced maximal capacity and 50% reduced insulin sensitvity to
insulin stimulated glucose disposal in cirrhotic subjects (Iversen et
a^ 1984).
The observation that the maximum capacity for lipogenesis
differed between the three aetiological sub-groups reported here is
surprising. It has previously been assumed that the metabolic
effects of the cirrhosis would overshadow any differences associated
with different aetiologies. Interpretation of this observation is
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complicated by the lack, of matching for sex and percentage ideal body
weight between the sub-groups. The P.B.C. group were all female,
were significantly thinner and had smaller adipocytes than the
alcoholic or cryptogenic groups. A large series of studies upon
normal males and females showed significantly higher rates of
lipogenesis in females, whether the results were expressed per cell
surface area or per cell number (Pedersen et_ al_ 1982a), but this
observation does not explain the findings in the cryptogenic group.
Severity of cirrhosis, as judged from clinical features, standard
liver function tests and histological picture, did not differ between
the groups although it is possible that hepatocyte function is better
preserved in P.B.C. for an equivalent elevation of serum bilirubin
and transaminase (Vierling 1982). The effect of alcohol ingestion
upon maximal capacity for lipogenesis is not known, but as the
subjects had been observed for at least 24 hours before biopsy, any
such effect could not be a result of acute toxicity of alcohol, but
may represent a chronic effect of the drug upon adipocytes.
In conclusion, this study has revealed important differences in
adipocyte metabolism between the aetiological sub-groups of cirrhosis
examined, despite the apparent similarity in severity of cirrhosis.
All three sub-groups exhibited significant iri vivo insulin
resistance, but the patients with P.B.C. were less insulin resistant
than those with alcoholic and cryptogenic cirrhosis. The alcoholic
cirrhosis patients showed the greater reduction in adipocyte insulin
binding and a sub-normal maximal stimulation of lipogenesis. The
adipocytes from patients with cryptogenic cirrhosis differed from
those of the alcoholic group mainly in achieving much higher rates of
lipogenesis in response to insulin stimulation. The effect of chronic
exposure to alcohol appears striking, but the precise cause of the
differences between the groups must await further studies, not least
because of the lack of matching of patient characteristics between
the sub-groups and the control group. All the cirrhotic subjects
studied displayed a major defect in adipocyte insulin sensitivity and
this was reflected in the severe in vivo insulin resistance of this
condition.
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CHAPTER FIVE
CHRONIC RENAL FAILURE
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INTRODUCTION
The occurrence of impaired glucose tolerance in chronic renal
failure has been recognised for over 70 years (Neubauer 1910). The
possibility of inadequate insulin secretion was debated until the
advent of radioimmunoassay of serum insulin, whereafter elevated
serum I.R.I, responses to oral glucose were uniformly observed
(Hampers et al 1968, Spitz et al 1970, DeFronzo et^ al^ 1978a). The
combination of impaired glucose tolerance and elevated serum I.R.I,
suggested that insulin resistance was a feature of chronic renal
failure. Insulin resistance in. vivo could be a result of defects in
insulin action in the liver, in the peripheral tissues or at both
sites. The question of decreased sensitivity of peripheral tissues to
insulin was approached directly by Westervelt (1969) who demonstrated
that glucose uptake by the forearm muscle of uraemic patients was
poorly stimulated by an exogenous insulin infusion. Spitz and
colleagues (1970) noted decreased effectiveness of intravenous
insulin in decreasing blood glucose and serum phosphate levels and
concluded that muscle was insensitive to insulin in chronic renal
failure. At the insulin concentrations used in euglycaemic clamp
studies which also demonstrated insulin resistance (DeFronzo et_ al
1981b, Smith & DeFronzo 1982) it is likely that the insulin
sensitivity of muscle and fat, rather than liver, was examined
(DeFronzo ejt ehl 1983a). Hepatic glucose output in uraemic subjects
suppressed normally at high physiological levels (Smith & DeFronzo
1982), but the possibility remains of hepatic insulin resistance at
basal or low serum insulin levels. In uraemic rats, hepatic insulin
resistance has been observed (Kauffman & Caro 1983). Hence, a defect
in peripheral insulin sensitivity is established and the degree of
hepatic insulin sensitivity is uncertain.
The cellular mechanism of insensitivity to insulin in chronic
renal failure is uncertain. Evidence for the presence of circulating
inhibitors of insulin action was put forward first by Westervelt and
Schreiner (1962) and at intervals since (Glaze et^ al_ 1967, Dzurik e£
al 1969, Milutinovic et_ al_ 1983, Lockwood & McCaleb 1983). The nature
of any such substance and its mode of action remains obscure.
Elevations of growth hormone, Cortisol, parathyroid hormone and
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glucagon do not. correlate with the degree of insulin resistance or
glucose intolerance (Spitz et_ al 1970, DeFronzo et al 1983b). Studies
of insulin receptors on circulating blood cells have yielded
conflicting results, decreased receptor number on erythrocytes
(Gambhir et_ al^ 1980 & 1981a) and normal receptor number on monocytes
(Smith & DeFronzo 1982) having been observed. Resistance to insulin
action at an intracellular, post-binding site was suggested by the
finding of decreased insulin mediated glucose disposal in vivo even
at serum insulin concentrations sufficient to achieve maximal insulin
receptor occupancy (Smith & DeFronzo 1982).
The effects of dialysis treatment upon abnormalities of
carbohydrate metabolism have been assessed. Uraemic patients on
maintenance haemodialysis show improved glucose tolerance without a
change in the serum I.R.I, response (Hampers et a\_ 1968) and insulin-
dependent diabetic patients on treatment require less insulin both
basally and post-prandially (Schmitz et_ ad 1984). These findings
suggest an increase in insulin sensitivity. Direct measurement of
insulin sensitivity using the euglycaemic clamp technique confirmed
this hypothesis (DeFronzo et al 1978a). However, neither glucose
tolerance nor tissue insulin sensitivity return to normal during
chronic haemodialysis. Continuous ambulatory peritoneal dialysis
(C.A.P.D.) is associated with a more normal life-style and better
general health (Ramos et al 1983). A strict diet is not necessary
during this form of dialysis and an adequate carbohydrate intake is
assured, 80 to 250 grams of glucose per day being absorbed from the
dialysate via the peritoneal cavity (Heaton et al 1983). Total energy
intake on C.A.P.D. does not rise markedly as dietary intake tends to
be spontaneously reduced (Heaton et_ jd 1984). The impact of C.A.P.D.
upon the tissue insulin sensitivity in chronic renal failure is
unknown. In order to study the cellular changes associated with renal
failure and the effect of C.A.P.D., adipocyte insulin binding,
adipocyte insulin sensitivity and glucose tolerance were examined in
a group of patients with advanced renal failure before and after
three months of treatment.
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SUBJECTS AND PROTOCOL
Nine subjects with chronic renal failure were recruited to the
study. The selection criteria required that the subjects were 20 to
65 years of age, taking an adequate diet, generally fit and not
receiving steroid therapy. None had a family history of diabetes. All
subjects were about to commence C.A.P.D. therapy as renal function
was steadily deteriorating. Each subject underwent a fat biopsy and a
75 gram oral glucose tolerance test. Six subjects were asked to
participate in a repeat study after three months on C.A.P.D. Five
were successfully restudied, the sixth patient suffering a fatal
myocardial infarction before the tests were due to be repeated. In
order to avoid significant glucose absorption from the peritoneal
cavity over the ten hours prior to investigation, subjects on
C.A.P.D. omitted their usual 2200 h peritoneal fluid exchange on the
evenings before tests. The uraemic group were compared to an age and
sex matched group of healthy subjects. Clinical and metabolic data on
the uraemic group, the uraemic subgroup restudied on C.A.P.D. and the
normal control group are given in Table 5.1.
RESULTS
a) Oral glucose tolerance test
Fasting blood glucose levels were significantly elevated in the
uraemic group compared with the control group (5.0 + 0.2 vs 4.1 +_ 0.1
mmol/1 respectively; p < 0.001) and remained so throughout the test
(Figure 5.1). Maximum blood glucose levels were achieved after 60
minutes in the uraemic group and after 30 minutes in the control
group. Seven of the nine uraemic subjects displayed impaired glucose
tolerance (W.H.0. 1982) but two subjects did not rise above 8.5
mmol/1 and fell to 4.8 and 2.1 mmol/1 respectively at 120 minutes
after the glucose load. Serum I.R.I, levels in the uraemic group were
not significantly elevated in the fasting state (9.7 hh 1.3 vs 6.8 +
0.9 mU/1). The maximum incremental rises were not significantly
different in the uraemic group despite the continuing stimulus of
hyperglycaemia, but serum I.R.I, remained significantly elevated
after 90 minutes (Figure 5.1). Elevation of fasting serum proinsulin
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(30.6 +_ 6.0 vs 17.2 +_ 2.7 pmol/1) accounted entirely for the slight
increase in fasting serum I.R.I, in the uraemic group. Peak serum
proinsulin levels were delayed in the uraemic group, but correction
of I.R.I, data for proinsulin crossreactivity did not obviate the
apparent hyperinsulinaemia after 90 minutes (Figure 5.2). Fasting C-
peptide levels in the uraemic group were markedly elevated (1.13 +_
0.13 vs 0.34 +_ 0.03 nmol/1; p < 0.001) and rose continuously
throughout the test (Figure 5.1).
In the five subjects restudied during C.A.P.D., fasting blood
glucose levels were found to have returned towards normal compared
with before dialysis (4.5 + 0.1 vs 5.3 + 0.3 mmol/1; p < 0.001). The
shape of the blood glucose profiles remained very similar, but blood
glucose levels were consistantly lower throughout the test (Figure
5.3). Serum I.R.I, levels were almost identical before and during
C.A.P.D. both fasting (9.7 + 1.3 vs 9.6 +_ 0.7 mU/1) and after glucose
ingestion (51.6 +_ 5.0 vs 51.0 +_ 3.1 mU/1 at 60 minutes; Figure 5.3).
Serum proinsulin levels both fasting and during the glucose tolerance
test were not changed by C.A.P.D. Fasting C-peptide levels appeared
slightly higher during C.A.P.D. (1.14 0.11 vs 1.76 _+ 0.43 nmol/1)
and rose more rapidly in the C.A.P.D. group, becoming significantly
different from the pre-dialysis group at 30 and 45 minutes after the
glucose load (Figure 5.3).
b) Adipocyte insulin binding
Maximum specific insulin binding was 2.55 +_ 0.23 vs 2.57 _+ 0.09
2
% per 10 cm cell membrane in the uraemic and control groups
respectively (Figure 5.4). The insulin concentrations at which half-
maximum binding was observed were 91+8 pmol/1 (uraemic) and 139 +
11 pmol/1 (control) (p < 0.005). This indication of raised receptor
affinity in the uraemic group was borne out by Scatchard analysis
(Figure 5.4). The slopes of the high affinity portion of the curves
were -0.021 +_ 0.003 and -0.010 + 0.001 for uraemic and control groups
respectively (p < 0.001) and those of the low affinity portion of the
curves were -2.85 +_ 0.52 vs -1.95 + 0.21 (not significant). The
number of high and low affinity insulin receptors was smaller in the
uraemic group (3.9 +_ 0.4 vs 7.5 0.6; p<0.001 and 44.5 +_ 4.1 vs 63.3
1^4.9 per ^ cell membrane; p<0.01).
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Maximum specific insulin binding fell in all subjects during
C.A.P.D. (2.95 +_ 0.23 vs 2.12 +_ 0.19 % per 10 cm^ cell membrane;
p < 0.05) (Figure 5.5). Half-maximum binding was observed at 86 +_ 14
and 98 + 10 pmol/1 (N.S.). Scatchard analysis suggested that the
observed change in maximum specific binding was a result of modest
changes in both affinity and number of high affinity receptors (slope
-0.025 + 0.004 vs -0.020 +_ 0.003 and receptor number (3.7 +_ 0.7 vs
3.2 _+ 0.5 per jum^).
c) Adipocyte insulin sensitivity
Basal and maximal rates of lipogenesis were similar in the
uraemic and control groups (47.5 +_ 6.5 vs 54.6 + 8.4 and 120 +_ 24 vs
o
122 + 15 pmol per 10 cm cell membrane per 90 minutes respectively).
Half-maximal stimulation of lipogenesis was observed at 13.5 + 4.4 and
21.4 4- 3.0 pmol/1 respectively (N.S.) (Figure 5.6).
During C.A.P.D., basal rates of lipogenesis were unchanged but
maximally stimulated rates of lipogenesis appeared lower (116 + 38 vs
82 + 19 pmol per 10 cm^ per 90 minutes; N.S.).The dose
response curve was slightly shifted to the right during C.A.P.D.
(half-maximal stimulation at 13.9 +_ 4.7 vs 29.0 +_ 13.0 pmol/1; N.S.)
(Figure 5.7).
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URAEMIC CONTROL URAEMIC URAEMIC
SUBJECTS SUBJECTS PRE-CAPD POST-CAP!
n=9 n=12 n=5 n=5
Age (years) 45.6+5.1 42.1+3.5 48.6+7.7 49.1+7.7
Male/female ratio 5/4 6/6 2/3 3/2
% I.B.W. 105+3 114+4 109+5 110+5
Duration of uraemia (years) 4.2+1.2 - 2.4+0.2 2.8+0.2
Diet - energy (kcal/day) 2059+216 2360+126 1939+353 2223+297
- carbohydrate (g/day) 238+30 241+24 204+38 319+38
Adipocyte diameter (p) 90+6 102+5 96+10 101+12
Serum creatinine (pmol/1) 1010+61 77+4 981+82 784+84
Serum bicarbonate (mmol/1) 16.2+1.1 25.1+0.4 17.4+1.7 23.0+0.3
Serum P.T.H. (U/l) 2.6+0.3 - 2.8+0.5 1.3+0.4
TABLE 5.1 Clinical and metabolic characteristics of the subjects
with chronic renal failure, the normal control group
and the subgroups of uraemic subjects studied both
before and during C.A.P.D.
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FIGURE 5.1 Mean blood glucose, serum I.R.I. and serum C-peptide
responses to a 75 gram oral glucose load.
Uraemic n = 9 (• •) and control n = 12 (o o) groups.
* p < 0.01 * p < 0.001
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FIGURE 5.2 Mean serum proinsulin levels during glucose tolerance
test.
Uraemic n = 9 (• • ) and control group n = 6 (o o).
* p< 0.05
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FIGURE 5.3 Mean blood glucose, serum I.R.I, and serum
C-peptide responses to a 75 gram oral glucose load.
Uraemic subjects (n = 5) before (• • ) and
after C.A.P.D. (o o).
* p < 0.05 * p < 0.001
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FIGURE 5.4 Specific insulin binding to adipocytes shown as
binding displacement curves and Scatchard plots.
Uraemic (•■ • ) and control (o o) subjects.
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FIGURE 5.5 Specific insulin binding to adipocytes shown as
binding displacement curves and Scatchard plots.
Uraemic subjects (n = 5) before (• • ) and
after C.A.P.D. (o- o).
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FIGURE 5.6 Insulin stimulation of lipogenesis shown as absolute
rates (top) and as percentage stimulation (bottom).
Uraemic n = 9 (•—• ) and control n = 12 (o—o) subjects.
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FIGURE 5.7 Insulin stimulation of lipogenesis shown as absolute
rates (top) and as percentage stimulation (bottom).
Uraemic subjects (n = 5) before (• • ) and
after C.A.P.D. (o o).
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DISCUSSION
The uraemic group exhibited the anticipated fasting
hyperglycaemia associated with normal serum insulin levels. This
suggestion of insulin resistance was borne out by the prolonged
hyperglycaemia despite marked hyperinsulinaemia in the last hour of
the glucose tolerance test. However, peak serum I.R.I was lower and
delayed in the uraemic group. The slower rate of gastric emptying and
hence slower intestinal absorption which has been documented in
uraemia could partially account for these changes (Craig et_ al_ 1983),
but the possibility remains of blunted insulin secretory capacity.
It has been reported that the first phase insulin secretion is
impaired in chronic renal failure (Hampers et_ aT 1966) but
hyperglycaemic clamp studies found normal insulin secretion (DeFronzo
et al 1982). Measurement of C-peptide does not resolve the question
of the normality of insulin secretion rates as C-peptide clearance is
grossly impaired in chronic renal failure and this results in
markedly elevated levels both fasting and after the glucose load.
The fasting hyperglycaemia is most probably a consequence of
lack of suppression of hepatic glucose output (DeFronzo et al 1983b)
secondary to hepatic insulin resistance. Rubenfeld & Garber (1978)
observed a 38% increase in fasting hepatic glucose output in uraemic
subjects who exhibited the fasting hyperglycaemia observed in most
studies (Neubauer 1910, Linder et_ al_ 1925, Hampers £t_ 1968, Spitz
et al 1970, DeFronzo et_ al^ 1978a, Heaton et_ el! 1984). However,
DeFronzo has described a group of uraemic subjects of similar
clinical and biochemical characteristics who had normal fasting
hepatic glucose output and blood glucose levels (DeFronzo et_ al^
1981b, Smith & DeFronzo 1982). Serum I.R.I, levels were very high in
this group, and hence the possibility remains of hepatic insulin
resistance in the fasting state. In the same subjects, hepatic
glucose output was observed to suppress almost normally at high
physiological serum insulin levels, but responsiveness rather than
sensitivity was examined. In a rat model of chronic renal failure,
isolated hepatocytes were shown to be insulin insensitive in respect
of stimulation of amino acid uptake (Kauffman & Caro 1983).
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The post-glucose hyperglycaemia observed in the present study
could result from both hepatic and peripheral insulin resistance as
under conditions of hyperinsulinaemia prevailing in the latter part
of the glucose tolerance test, hepatic glucose output and uptake is
almost normal and peripheral insulin resistance is present (DeFronzo
et al 1981b, Smith & DeFronzo 1982, Westervelt 1969). In contrast to
the uncertainty surrounding hepatic insulin sensitivity, peripheral
insulin sensitivity has been shown to be decreased in uraemia by
direct studies of human forearm or leg (Westervelt et al 1969,
DeFronzo et_ ad 1981b) and by the euglycaemic clamp technique
(DeFronzo et_ al_ 1981b, Smith & DeFronzo 1982). The iii vivo assessment
of insulin-mediated glucose disposal is approximately 85% dependent
upon muscle and 15% dependent upon adipose tissue (DeFronzo et_ al_
1981a). Muscle and adipose tissue are however exposed to identical
controlling influences and adipocytes have been observed to exhibit
the insulin resistance predicted from in vivo studies (Olefsky 1976,
Kolterman et_ al^ 1981, Pedersen et al 1981c, Hjollund et_ aT 1983c).
The present observations of normal maximum specific insulin binding
and normal adipocyte insulin sensitivity in chronic renal failure
were therefore unexpected.
Specific insulin binding to adipocytes from uraemic subjects was
normal because increased affinity of the receptors compensated for
the low receptor number. Several clinical states, such as hypocaloric
dieting in obesity (Beck-Nielsen et_ ad 1979a), Cushing's syndrome
(Muggeo et_ cil 1983a) and acromegaly (Muggeo et_ al 1979 & 1983b) have
been shown to be associated with increased monocyte insulin receptor
affinity. The dietary intake of the uraemic subjects was only
marginally and not significantly lower than that of the normal
subjects in the present study. Mean diurnal serum total Cortisol
level is elevated in uraemia, but this could be secondary to binding
protein abnormalities (Heaton et_ al_ 1984). Serum growth hormone has
been reported to be raised in some studies (Orskov & Christensen
1971) but not in others (Heaton et_ ad 1984). Neither serum Cortisol
nor growth hormone levels correlate with glucose intolerance or
insulin resistance (DeFronzo et_ ad 1983, Heaton et_ al_ 1984). Hence,
the observed change in receptor affinity cannot be attributed to any
single recognised influence. Hyperinsulinaemia is the obvious factor
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to account for the reduced receptor number. Although the decrease in
receptor number cannot be ascribed to increase in fasting serum
insulin levels, mean diurnal serum insulin levels are markedly raised
in uraemic subjects (Heaton et_ al 1984). There was no correlation
between fasting serum insulin and high or low affinity receptor
numbers. Insulin receptor number in uraemia has been reported to be
decreased on erythrocytes (Gambhir et^ al^ 1980 & 1981) but normal on
monocytes (Smith & DeFronzo 1982). In the latter study, the limited
range of insulin concentrations studied precluded any conclusions
about number or affinity of the high affinity receptor population. In
animal models of chronic renal failure, both normal affinity and
receptor number on adipocytes (Maloff et_ al_ 1983) and increased
receptor number on hepatocytes (Kauffman & Caro 1983) have been
reported.
In the present study, increased affinity of a decreased receptor
population was observed to be associated with normal in vitro
adipocyte insulin sensitivity as assessed by stimulation of
lipogenesis. It may be considered that the observation of normal
adipocyte insulin sensitivity in a clinical state known to be
associated with muscle insulin resistance in vivo constitutes the
first described example of differential tissue behaviour. This could
be so, but the evidence is indirect. An alternative explanation would
invoke the existence of factors which only operate Tn vivo,
confounding the interpretation of in vitro studies. Circulating
inhibitors of insulin action in uraemia have been described (Dzurik
et al 1969, Milutinovic et a_l 1983, Lockwood & McCaleb et_ al_ 1983),
but the nature of such a substance remains obscure. The slight but
chronic metabolic acidosis of uraemia could increase insulin
resistance (Whittaker et_ al_ 1981b & 1982) and reduce receptor
affinity (DeMeyts 1976). If partial compensation for the chronic
effect of either a circulating inhibitor or adverse physical
conditions were to develop at the cellular level, it is likely that
such an effect could persist during the period of JLn vitro study. All
cells were handled in the same supporting buffer at pH 7.42 in_ vitro.
Sudden removal of the inhibitory influence could lead to the cells
being more sensitive under the experimental conditions than under
habitual in vivo conditions.
94
After three months C.A.P.D. glucose tolerance was improved
although not returned to normal. The glucose tolerance curve was
shifted downwards but unchanged in shape, peak blood glucose levels
still being observed at 60 minutes compared to 30 minutes in the
normal control group. Serum l.K.I. levels both fasting and after the
glucose load were almost identical before and after C.A.P.D.,
suggesting that the improvement in glucose tolerance was secondary to
improved tissue senstivity to insulin, not improved pancreatic B cell
function. The fall in fasting blood glucose levels despite almost
identical serum insulin levels suggest that an improvement in hepatic
insulin sensitivity had occured during C.A.P.D. The slightly higher
fasting and post-glucose C-peptide levels could possibly be an effect
of further decline in renal function during the months of dialysis.
The effect of C.A.P.D. upon adipocyte insulin binding was the
opposite of that expected by consideration of the apparent
improvement in insulin sensitivity suggested by the glucose tolerance
test data. C.A.P.D. brings about changes in nutrition, acid-base
balance, serum lipids, physical activity and general well-being
(Ramos et jrl 1983). One possible explanation of the decrease in
adipocyte insulin binding could be that patients on C.A.P.D. are
never in the fasting state, peritoneal glucose absorption continuing
day and night. This induces persisting hyperinsulinaeraia (Heaton et
al 1984) which could down-regulate insulin receptors.
Despite the decrease in adipocyte insulin binding, In vitro
insulin sensitivity did not change significantly in the five patients
restudied. Changes in the post-binding pathways of insulin action,
counteracting the effect of decreased receptor binding may be
inferred. The glucose tolerance test data suggest improvement in
insulin sensitivity during C.A.P.D. which is likely to involve both
hepatic and peripheral tissues. If a circulating inhibitor of insulin
action had been at least partly removed by dialysis, then the insulin
sensitivity observed iri vitro could well reflect more closely that
operating in vivo, unlike the situation before dialysis.
In conclusion, normal insulin sensitivity and responsiveness
have been observed in adipocytes from subjects with advanced chronic
renal failure. This contrasts sharply with in vivo muscle insulin
resistance, and could be a result of the operation of circulating
inhibitors of insulin action. The possibility exists of differential
tissue behaviour with respect to insulin action iri vivo. Adipocyte
insulin receptors have been shown to be of higher than normal
affinity but reduced in number. C.A.P.D. brought about a decrease in
receptor affinity and in responsiveness to insulin, and adipocyte
insulin sensitivity remained normal. Glucose tolerance improved
during C.A.P.D. secondary to improved hepatic, and possibly
peripheral, insulin sensitivity. These data describe an unusual
adipocyte insulin receptor status and reflect the complexity of the
response of different tissues to the state of chronic renal failure.
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CHAPTER SIX
HYPERTHYROIDISM
97
INTRODUCTION
Hyperthyroidism is associated with marked metabolic
disturbances. Fasting hyperglycaemia has been reported in some
studies of hyperthyroid man (Ikejiri et_ aT 1978, McCulloch et al
1982, McCulloch 1983a) but others have not confirmed this (Hales &
Hyams 1964, Saunders et_ jtl 1980). Hyperglycaemia following
glucose or mixed meals has frequently been described (Hales and
Hyams 1964, Ikejiri et_ aT 1978, Saunders et_ al^ 1980, McCulloch et al
1982). Fasting plasma non-esterified fatty acid and glycerol
concentrations are elevated in hyperthyroidism (McCulloch et al
1983a). The processes underlying these alterations in circulating
concentrations of glucose, non-esterified fatty acids and glycerol
have been extensively investigated.
Increased hepatic glucose output could cause fasting
hyperglycaemia and has been demonstrated (Saunders et_ aT 1980, Perez
et al 1980, McCulloch et^ a_l 1983b) in all but one study (Wahren et_ gT
1981). Enhanced gluconeogensis may be inferred from the observation
of increased hepatic uptake of the major gluconeogenic precursors,
especially glycerol (McCulloch et al 1983b). Hepatic glycogen stores
are decreased in hyperthyroid man (Hoch 1962, Movitt et_ al^ 1963) and
the demonstration of more rapid depletion of glycogen stores in the
perfused livers of hyperthyroid rats suggests that increased
glycogenolysis rather than decreased glycogen synthesis may be the
mechanism (Laker & Mayes 1981). Hence, increased rates of both
gluconeogenesis and glycogenolysis could contribute to an increased
hepatic glucose output. Post-prandial hyperglycaemia has been
suggested to be a consequence of rapid gastric empying (Holdsworth
and Besser 1968), but there is no evidence to support this concept
and peak blood glucose levels occur at a normal time after oral
glucose or mixed meals (McCulloch et al_ 1982). Reduced hepatic
extraction of glucose is a possible factor, secondary either to
reduced fractional extraction and normal hepatic blood flow, or to
increased hepatic blood flow with normal or reduced fractional
extraction (Wahren et^ al 1981). Increased peripheral tissue lipolysis
is associated with increased turnover rates of both non-esterified
fatty acids and glycerol (Saunders et al 1980, McCulloch et_ al_
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1983b).
The altered regulatory mechanisms which bring about the
characteristic abnormalities of hyperthyroidism are at present
uncertain. The enhanced adipose tissue lipolysis has been suggested
to be a result of increased sensitivity to catecholamines
(Christensen 1973), but beta-blockade does not suppress this (Beylot
et al 1980, Saunders et^ al_ 1980). Some hyperthyroid subjects have
elevated plasma glucagon levels with impaired suppression following
an oral glucose load (Kabadi & Eisenstein 1980). Reduced insulin
action could theoretically precipitate all of the observed
abnormalities. Measurement of serum I.R.I, has dismissed the concept
of a hypoinsulinaemic state, fasting serum I.R.I, concentration
having been found to be normal (Holdsworth & Besser 1968, McCulloch
et al 1982, McCulloch et_ al^ 1983) or elevated (Doar et^ al_ 1969), with
the I.R.I, response to an oral glucose load being normal. The
observation of normal or high levels of circulating I.R.I, in the
face of impaired glucose tolerance and unrestrained lipolysis has
raised the possibility of hepatic and peripheral insulin resistance.
Examination of insulin sensitivity in hyperthyroid man has produced
conflicting results, both enhanced (Elrick et^ al 1961) and decreased
(West et_ al^ 1975, Ikerjiri et^ al_ 1977) insulin sensitivity having
been reported.
Direct examination of segments of adipose tissue from
hyperthyroid subjects suggested decreased sensitivity to insulin, the
dose-response curve for anti-lipolysis being right-shifted, but with
a normal maximal response (Wennlund ej^ al_ 1981). However, isolated
adipocytes from hyperthyroid rats were found to have not only normal
sensitivity and responsiveness to insulin stimulation of lipogenesis,
but also greatly increased numbers of insulin receptors (Heise et al
1982).
In view of the possibility of peripheral tissue insulin
resistance contributing to the metabolic abnormalities of
hyperthyroidism, the present studies were designed to elucidate the
insulin sensitivity and insulin receptor status of adipocytes from
patients with hyperthyroidism, and to relate this to the pattern of
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insulin secretion in response to oral glucose.
SUBJECTS AND PROTOCOL
Thirteen patients referred to the clinic with a provisional
diagnosis of hyperthyroidism were recruited to the study. No prior
treatment had been given to any subject. The subjects were
subsequently divided into hyperthyroid and control groups on the
basis of total serum thyroxine and thyrotrophin releasing hormone
tests. The control subjects had no evidence of any organic disease
which may have produced the presenting symptoms, and thus constituted
a group of subjects who had similar symptoms of adrenergic
overactivity but who did not have elevated serum thyroid hormone
levels. The clinical and biochemical characteristics of the two
groups are listed in Table 6.1. Fasting adipocyte tissue biopsies and
oral glucose tolerance tests were performed on each subject within a
three day period.
RESULTS
a) Oral glucose tolerance tests
Mean fasting blood glucose was 4.9 _+ 0.3 mmol/1 for the
hyperthyroid groups compared with 4.4 +_ 0.2 mmol/1 for the control
group (p < 0.1 >0.05). The rise in blood glucose was greater in the
hyperthyroid group, being significantly different at 10, 25, 30, 45
and 90 minutes (p < 0.05) (Figure 6.1). Fasting serum I.R.I, levels
were similar in the two groups (9.5 +_ 2.8 vs 7.5 +_ 0.8 mU/1 for
hyperthyroid and control groups respectively). Peak serum I.R.I, was
69.0 _+ 6.8 mU/1 for the hyperthyroid group (at 45 min) and 54.3 +_ 8.8
mU/1 for the control group (at 60 min)(p < 0.1 > 0.05). Fasting
serum proinsulin was very similar in the two groups (14.1 +_ 3.8 vs
15.8 +_ 3.2 pmol/1 respectively) but rose more steeply to a higher peak
in the hyperthyroid group (64.8 + 7.3 vs 39 +_ 3.7 pmol/1 at 60 min;
p < 0.01) (Figure 6.2). Correction of measured I.R.I, for proinsulin
cross-reactivity in the insulin assay further diminishes the
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difference in mean peak I.R.I, levels. Serum C-peptide levels were
similar both basally (0.46 + 0.11 vs 0.37 +_ 0.04 nmol/1
respectively) and throughout the oral glucose tolerance test (Figure
6.1).
b) Adipocyte insulin binding
The binding displacement curve is shown in Figure 6.3. Maximum
specific insulin binding was 1.80 + 0.18% for the hyperthyroid group
and 2.62 _+ 0.27% for the control group (p < 0.025). The difference in
specific insulin binding was significant at all points up to an
insulin concentration of 2.2 nmol/1 insulin. Half-maximum binding was
observed at total insulin concentrations of 145 + 16 and 120 + 8
pmol/1 respectively (p > 0.1). Scatchard analysis of this data
yielded parallel plots (Figure 6.3) suggesting that the difference in
binding was secondary to reduced receptor number rather than any
alteration of affinity. There was a negative correlation between
maximum specific binding and total serum thyroxine within the
hyperthyroid group (Rg = 0.71, p < 0.05) (Figure 6.4).
c) Adipocyte iusuliu sensitivity
The rates of adipocyte lipogenesis were 52.0 + 16.0 and 87.0 +
14.4 pmol/10 cm /90 min basally for the hyperthyroid and control
groups respectively (p < 0.1 > 0.05) and 121.5 +_ 28.0 and 175.8
25.4 pmol/10cm^/ 90 min with maximal insulin stimulation respectively
(p > 0.1). Insulin stimulation achieved similar percentage increases
above basal levels in each group and the insulin concentrations
required to achieve half-maximal stimulation were similar (13.9 + 3.6
O
vs 11.4 _+ 2.1 pmol/10 cm /90 min respectively) (Figure 6.5).
The basal rate of glucose transport was 0.75 + 0.22 pmol/10
o
cm /20 sec for the hyperthyroid subjects studied (n = 3) and 1.00 +
0.22 pmol/lOcm / 20 sec for the control subjects studied (n = 4).
The insulin concentrations required to achieve half-maximal
stimulation were almost identical (24.3 _+ 2.2 vs 24.6 + 3.6 pmol/10
cm^/20 sec respectively) (Figure 6.6).
Sex
Age (years)
% I.B.W.
Adipocyte diameter (p)
Diet - grams
carbohydrate /day
Diet - kcal /day
Total serum thyroxine
(nmol/1)
THYROTOXIC
n = 7
Female
53.4 + 3.5
100 + 4
97 + 5
208 + 14
1904 + 160
252 + 25
CONTROL
n = 6
Female
41.5 + 4.8
108 + 9
105 + 7
200 + 18
1958 + 116
117 + 9
TABLE 6.1 Clinical and metabolic characteristics of the hyperthyroid
and control groups. The only significant difference was
that in serum thyroxine levels (p <0.001).
FIGURE 6.1 Mean blood glucose, serum I.R.I, and serum C-peptide
responses to a 75 gram oral glucose load.
Hyperthyroid (• • ) and control (o o) groups.
* p < 0.05
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FIGURE 6.2 Mean serum proinsulin levels during the glucose
tolerance test.
Hyperthyroid (•—• ) and control (o—o) subjects.
* p < 0.05
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FIGURE 6.3 Specific insulin binding to adipocytes shown as
binding displacement curves and Scatchard plots.
Hyperthyroid (• • ) and control (o o) subjects.
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FIGURE 6.4 Relationship between specific insulin binding to
adipocytes and total serum thyroxine in the hyperthyroid
group (•). Rg = 0.71; p< 0.05. Control data is shown as
mean + SEM (o).
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FIGURE 6.5 Insulin stimulation of lipogenesis in adipocytes shown
as absolute rates (top) and as percentage stimulation
(bottom). The dotted line indicates the insulin
concentrations at which half-maximal stimulation were
observed.
Hyperthyroid (• • ) and control subjects (o o).
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FIGURE 6.6 Insulin stimulation of glucose transport in adipocytes
shown as absolute rates (top) and as percentage stimulation
(bottom). The dotted line indicates the insulin
concentrations at which half-maximal stimulation were observed.
Hyperthyroid (• • ) and control subjects (o o).
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DISCUSSION
In previous studies of hyperthyroid patients, elevated fasting
and post-prandial blood glucose concentrations (McCulloch et_ al
1982a) and increased glucose production rates (McCulloch ejt al_ 1983b)
have been observed despite normal serum insulin levels. The present
study was designed to investigate insulin secretion, tissue insulin
receptor status and insulin sensitivity in hyperthyroid and normal
subjects.
Hyperglycaemia following oral glucose administration was
observed in this as in many previous studies. However, serum insulin
levels were not significantly different in the two groups. It has
been suggested that much of the insulin measured by standard
radioimmunoassay in hyperthyroidism may in fact be proinsulin
(Sestoft & Heding 1981). Proinsulin hypersecretion in hyperthyroidism
was observed in the present study, and as proinsulin was found to
exhibit 50% crossreactivity with insulin in the insulin assay used,
it is apparent that the observed peak immunoreactive insulin levels
would be affected by the proinsulin present. The true insulin levels
are closer in the two groups than the I.R.I, levels suggest. The
finding of normal C-peptide responses to oral glucose in the present
study confirms that the insulin secretion itself was normal, insulin
and C-peptide being secreted in equimolar amounts. Hence, the
hyperthyroid subjects displayed resistance to insulin action either
in promoting hepatic glucose uptake, in inhibiting hepatic
gluconeogenesis or in promoting glucose uptake into the peripheral
tissues, muscle and fat.
The adipocyte insulin binding studies demonstrated that insulin
receptor number was decreased in hyperthyroidism, corroborating
recently reported observations (Arner et^ al_ 1984a). This finding is
in sharp contrast to the demonstration that the adipocytes of rats
rendered acutely hyperthyroid almost doubled their insulin receptor
number (Heise e_t a_l 1982). The possiblity of a species difference
cannot be dismissed, but studies after more prolonged periods of
thyroxine administration to rats would be of interest. The time
course of the cellular insulin receptor response to continued
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stimulation by thyroid hormones requires further study in view of the
possibility of initial increase in synthesis rate or recruitment from
a latent pool of insulin receptors (Deutsch et al 1982) followed by
compensatory downregulation. To date, few factors have been shown to
be involved in the physiological control of insulin receptor number,
insulin itself being by far the most powerful influence (Gavin et al
1974, Marshall & Olefsky 1980, Pezzino et_ al^ 1980). The results of
the present study suggest that thyroid hormones may be involved in
the control of insulin receptor number. The inverse correlation
between total serum thyroxine and adipocyte insulin binding, which
was also observed by Arner and colleagues (1984a), adds weight to
this hypothesis.
Adipocyte insulin resistance is usually present in those
clinical states associated with reduced adipocyte insulin receptor
number, such as obesity (Olefsky 1976, Pedersen et al^ 1981c),
diabetes (Pedersen & Hjollund 1982, Olefsky et^ al 1982a) and
cirrhosis (Taylor et_ al_ 1984a). However, the insulin concentrations
required to achieve half-maximal stimulation of both glucose
transport and lipogenesis were similar for the adipocytes of the
hyperthyroid and control groups. The adipocytes from the hyperthyroid
subjects thus exhibited not only receptor downregulation but also
compensation for the receptor alteration at the post-binding level. A
dissociation of biological effects from change in adipocyte insulin
receptor number was also observed after acute thyroxine
administration to rats (Heise et_ <1 1982), although in this case
insulin receptor number increased without change in adipocyte insulin
sensitivity. The explanation for this phenomenon is obscure but fuels
the concept that the linkage between receptor binding and insulin
action is not simple. The observation that adipose tissue from
hyperthyroid subjects did not exhibit normal sensitivity to insulin
inhibition of lipolysis and stimulation of total glucose oxidation
(Wennlund et_ al 1981) suggests that the regulation of these post-
binding pathways in hyperthyroidism differs from that of the glucose
transport and lipogenesis pathways. The possiblity of peripheral
resistance to insulin action has recently been investigated iri vivo
using the glucose clamp technique (McCulloch et al 1983a). The
stimulation of glucose disposal by exogenously administered porcine
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insulin was identical in hyperthyroid and control subjects but there
was resistance to suppression of lipolysis during insulin infusion
(McCulloch et^ a\_ 1983a) implying differential regulation of the post-
binding pathways of insulin action.
An alternative explanation of the insulin action data could take
into account the absolute basal rates of lipogenesis and glucose
transport. The basal rates of both processes appear to be lower in
the hyperthyroid group, albeit not statistically significantly with
the small numbers studied. It is possible that the measured basal
rates :Ln vitro reflect a reduced tonic stimulation iri vivo as a
result of normal tissue insulin concentrations acting through reduced
numbers of insulin receptors. The enzymes responsible for lipogenesis
may be expected to be less induced than in normal cells. If any given
insulin-generated signal reaching the cell cytoplasm brings about a
certain absolute increase in in_ vitro rates of lipogenesis or glucose
transport then the effect on the adipocytes of the hyperthyroid group
would be smaller, being mediated through reduced receptor numbers.
The same insulin concentration would be expected to bring about a
greater increase in non-hyperthyroid adipocytes. However, the
percentage increase may be similar in both cases because of the
difference in basal rates. In this manner, the use of the traditional
measure of insulin sensitivity may mask the functional effects of the
low insulin receptor number in the in vitro system. There is,
however, no direct evidence to confirm this hypothesis, and the
former interpretation of the data must be favoured.
The apparently normal sensitivity of adipocytes from
hyperthyroid subjects to insulin stimulation of glucose transport and
lipogenesis accords with the recent demonstration of normal
peripheral tissue sensitivity to exogenously administered insulin in
man (McCulloch et al 1983a). The elimination of peripheral tissue
resistance to glucose disposal as a possible cause of post-prandial
hyperglycaemia makes defects of hepatic insulin sensitivity in
hyperthyroidism more likely. Indirect support for this hypothesis is
provided by the observation that hepatic glycogen stores are markedly
reduced in hyperthroidism (Hoch 1962, Maracek & Feldman 1973) and do
not increase after oral glucose (Mirsky & Broh-Kahn 1936). The only
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study of insulin binding to liver membranes from hyperthyroid rats
showed a 22% reduction in maximum binding, although small numbers
prevented statistical significance from being achieved (DeRuyter et_
a^L 1982).
In conclusion, normal insulin secretory responses but relative
hyperglycaemia following oral glucose have been observed in
hyperthyroidism. No abnormality of adipocyte insulin sensitivity
could be detected in vitro but adipocyte insulin receptor number was
reduced. These results suggest that thyroid hormones could play a
role in the control of insulin receptor number, this being modulated
in such a manner that cellular sensitivity to insulin stimulation of
lipogenesis and glucose transport remains unchanged. The normal
insulin sensitivity of adipocytes, together with the recent Tn vivo
observation of normal peripheral tissue insulin sensitivity suggest,
albeit indirectly, that disturbed hepatic insulin responsiveness
plays a major role in the glucose intolerance of hyperthyroidism.
CHAPTER SEVEN
BRITTLE AND STABLE INSULIN DEPENDENT DIABETES
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INTRODUCTION
Peripheral hyperinsulinaeraia may be regarded as a characteristic
feature of insulin-dependent diabetes (Asplin et al 1979).
Conventional subcutaneous administration of insulin in doses
sufficient to achieve adequate portal vein insulin concentrations,
and thus control of hepatic metabolism, must inevitably result in
peripheral hyperinsulinaemia. This is likely to induce compensatory
changes in insulin sensitivity and responsiveness in peripheral
target organ tissues such as muscle and adipose tissue. In vivo
studies have demonstrated decreased peripheral tissue insulin
sensitivity in insulin-dependent diabetes (Harano et^ aT 1981,
DeFronzo £t_ al_ 1982, Proietto ert_ al^ 1983). However, well controlled
insulin-dependent diabetic subjects, in whom the degree of
hyperinsulinaemia may be expected to be more exaggerated, have less
marked insulin resistance in vivo (Beck-Nielsen et_ al_ 1984, Reevers
et al 1984). This suggests that hyperinsulinaemia is not the decisive
factor per se, but that some aspect of metabolic control is important
in determining insulin sensitivity. Although the majority of insulin-
dependent diabetic subjects respond to insulin in a predictable
fashion, a small number exhibit fluctuating and pronounced resistance
to subcutaneously administered insulin. After exclusion of subjects
with recognised causes of erratic diabetic control, there remain a
small number of subjects whose metabolic contol may be described as
brittle.
The term "brittle diabetes" has been applied in many different
ways to states of unstable diabetic control. It was originally used
to describe a group of insulin-dependent diabetic patients who
experienced frequent and inexplicable oscillations between
hyperglycaemic ketosis and hypoglycaemia (Woodyatt 1937). The
definition was subsequently widened to include any diabetic whose
life was disrupted by episodes of either hyperglycaemia or
hypoglycaemia (Tattersall 1977). For the purpose of this study, the
term "brittle diabetes" was restricted to those subjects who were
referred for management of extremely unstable diabetes, no cause for
which could be identified, and who proved impossible to control on
subcutaneous insulin despite intensive in-patient supervision. This
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definition, which has been used by others (Pickup et_ a_l 1983), serves
to delineate those patients who present the most difficult problems
of management. These patients all require high doses of insulin
intramuscularly or intravenously, routes which achieve adequate
plasma free insulin levels in such patients (Pickup et al 1981, Home
et al 1982). Resistance to the action of insulin at the tissue level
therefore could explain the poor response of brittle diabetic
patients to appropriate insulin therapy.
The present studies were performed in order to test the
hypothesis that the abnormal response to insulin in brittle diabetes
is a consequence of pathology at the level of the insulin receptor or
subsequent steps of insulin action. Adipose tissue was chosen for
these studies, being metabolically important, capable of responding
to insulin in_ vitro and readily accessible. The results of studies
upon a group of brittle diabetic patients were compared with those of
matched groups of stable insulin-dependent diabetic and non-diabetic
subjects.
SUBJECTS AND PROTOCOL
Six insulin-dependent diabetic patients who had been referred to
Newcastle upon Tyne from other centres throughout Great Britain with
extremely unstable diabetes were studied. Prior to referral the
patients had suffered a mean of 19 (range 5-35) episodes of severe
ketoacidosis and over the six month period preceding referral had
spent 80 (range 42-120) days in hospital. No cause for the
unpredictable tendency to ketoacidosis could be identified, and no
patient could be controlled on subcutaneous insulin despite intensive
supervision. The control group of seven stable insulin-dependent
diabetic subjects were chosen to match the brittle group with respect
to age, sex, body weight and duration of diabetes (Table 7.1). Only
subjects with sub-optimal diabetic control were selected. A group of
young non-diabetic female subjects were also studied. The brittle
group were receiving more than twice the daily insulin dose of the
stable group, three by intramuscular injection and three by
intravenous infusion. All the control group were receiving
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subcutaneous insulin, one by continuous infusion and six by
intermittent injection of short and intermediate acting insulins.
Both diabetic groups were receiving carbohydrate restricted diets.
The brittle diabetic patients and one stable diabetic patient were
studied as in-patients, and six of the stable diabetic subjects were
studied as outpatients. Fasting fat biopsies were performed on each
subject after at least three days free of marked fluctuations in
diabetic control. Three brittle diabetic patients were restudied
after a period of three to nine months of stable diabetic control.
This was achieved in one subject by use of an external insulin
infusor (Siemens) delivering into the peritoneal cavity and in two
patients by use of a totally implanted pump (Infusaid) delivering
intravenously in one patient and intraperitoneally in the other.
RESULTS
a) Insulin Binding
The binding displacement curves are shown in Figure 7.1. Insulin
binding at tracer insulin concentrations was significantly reduced in
n
the brittle group (1.78 +_ 0.18 % per 10 cm cell membrane) compared
O
with the stable diabetic group (2.57 _+ 0.36 % per 10 cm cell
membrane; p < 0.05) who themselves were not significantly different
from control subjects (Table 7.2). The difference in binding between
brittle and stable diabetic patients was significant at all insulin
concentrations up to 120 pmol/1. Half-maximum displacement of tracer
insulin was observed at 206 +_ 42 for the brittle group and 122 + 13
pmol/1 for the stable group (p = 0.069). This suggestion of reduced
receptor affinity in the brittle group was borne out by Scatchard
analysis (Figure 7.1). The slope of the high affinity portion of the
Scatchard plot for the brittle group was found to be reduced but the
receptor number, as assessed from the x axis intercepts, was similar
in the two groups. Adipocyte insulin binding data for the normal
control group is summarized in Table 7.2.
b) Adipocyte insulin degradation
Total insulin degradation was similar in the presence of cells of
the brittle, stable diabetic and normal groups (1.14 + 0.04%, 1.36 +
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0.12% and 1.21 +_ 0.11% respectively at 60 minutes and 2.41 +_ 0.17%,
2.66 _+ 0.21% and 2.42 +_ 0.10% respectively at 120 minutes; Figure
7.2). Tracer insulin degradation in the presence of cold insulin (10
|jmol/l) did not increase markedly between 60 and 120 minutes whereas
the increase in tracer insulin degradation in the absence of cold
insulin increased linearly with time.
c) Adipocyte insulin sensitivity
Basal and maximal rates of lipogenesis were similar in the two
diabetic groups (75 + 14, 181 +_ 30 and 61 +_ 5, 187 + 37 pmol/1 per 10
cm^ per 90 min for brittle and stable groups respectively) (Figure
7.3). The insulin concentration required to achieve half-maximal
stimulation was 34 _+ 4 pmol/1 for the brittle group and 14 +_ 3 pmol/1
for the stable group (p < 0.01). The lipogenesis data for the stable
diabetic group were similar to those of the normal control group in
all respects (Table 7.2).
d) Relationship between adipocyte insulin binding and insulin
sensitivity
There was a negative correlation between maximum specific binding
to adipocytes and the insulin concentration required to achieve half-
maximal stimulation of lipogenesis (Figure 7.4) both for all subjects
(R0 = 0.78, p < 0.01) and for the brittle diabetic subjects alone (R„b b
= 0.89, p < 0.05).
e) Effects of achieving stable control
In the first patient who was studied twice, maximum specific
insulin binding increased secondary to a change in receptor affinity
and this was accompanied by an increase in insulin sensitivity in
vitro, the insulin concentration required to achieve half-maximal
stimulation of lipogenesis after intraperitoneal insulin being almost
identical to that for the stable diabetic group (Figure 7.5 and Table
7.3). In the other two patients, adipocyte receptor affinity appeared
to rise but maximum specific insulin binding did not change markedly
(Table 7.3). Adipocyte insulin sensitivity, as defined by the insulin
concentrations necessary to achieve half-maximal stimulation of
lipogenesis, increased in all three subjects although maximally
stimulated rates of lipogenesis appeared to decrease.
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BRITTLE STABLE NORMAL
DIABETIC DIABETIC SUBJECTS
PATIENTS PATIENTS
(n=6) (n=7) (n=6)
Sex ALL FEMALE
Age (years) 22+2 25+2 35+4
Ideal body weight (%) 128+8 132+5 112+9
Mean adipocyte diameter (^i) 107+6 110+3 106+7
Duration of diabetes (years) 10.6+3.0 14.3+2.0 -
Insulin dose (units/day) 134+17 57+6 -
Fasting plasma free insulin 41.3+18.2 11.2+1.4 8.C+0.7
(mU/1)
HbA1 (%) 12.6+1.3 11.1+0.5 -
Diet - grams carbohydrate/day 112+6 131+14 178+24
- Kcal/day 1146+81 1477+166 2010+126
- grams fat/day 67+5 79+7 98+1
TABLE 7.1 Clinical characteristics of the brittle diabetic, stable
diabetic and normal groups. There was no significant
difference between the brittle and stable diabetic group
apart from that in insulin dose (p = 0.001).
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Maximum specific binding
to adipocytes (%)
Insulin concentration for half
maximal displacement (pmol/1)
Basal lipogenesis
(pmoles per 10cm per 90 min)
Maximal lipogenesis
(pmoles per 10 cm per 90 min)
Half-maximal stimulation of
lipogenesis (pmol/1)
Total insulin degradation
at 60 min (%)
BRITTLE
DIABETIC
PATIENTS
(N=6)
1.78+0.18
206+42
75+14
181+30
34+4
1.1+0.1
STABLE
DIABETIC
PATIENTS
(N=7)
122+13
61+5
187+37
15+3
NORMAL
CONTROL
SUBJECTS
N=6)
2.57+0.36 2.81+0.18
113+10
68+13
173+29
13+2
1.4+0.1 1.2+0.1
TABLE 7.2 Adipocyte insulin binding, insulin sensitivity and insulin
degradation in the non-diabetic group, and in the stable
and brittle diabetic groups.
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Insulin
therapy
HbAj^
%
Insulin dose
U/Kg/day
Fasting P.F.I.
mU/1
Max specific
binding %
Half-max displ
pmol/1
Basal L.G.
pmol/90 min
Max L.G.
pmol/90 min
Half-max stim
pmol/1
SUBJECT 1
Initial Repeat
I.M. I.P.
12.2 9.1
1.64 0.57
10.1 20.4
1.15 1.90
375 110
74 89
202 169
46 12
SUBJECT 2
Initial Repeat
I.M. I.V.
18.2 10.0
2.59 0.82
14.0 32.2
1.75 1.65
125 106
59 46
107 92
44 6
SUBJECT 3
Initial Repeat
I.V. I.P.
9.2 8.5
2.13 0.90
36 30.6
1.85 1.72
200 120
87 55
246 143
32 23
TABLE 7.3 Individual adipocyte insulin binding and adipocyte insulin
action data and clinical data upon the three brittle
diabetic subjects re-studied after a period of stable
diabetic control.
P.F.I. - plasma free insulin; L.G. - lipogenesis;
max - maximum; displ - displacement
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FIGURE 7.1 Specific insulin binding to adipocytes shown as
binding displacement curves (top) and as Scatchard plots
(bottom).
Brittle diabetic (o—o), stable diabetic (•—• )
and non-diabetic (A--d) subjects.
0-00 4
Bound insulin (pmol/l)
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FIGURE 7-2 Degradation of tracer insulin in the presence of
adipocytes from brittle diabetic (o o) and stable
diabetic subjects (•—•):
in the presence of tracer insulin alone.
in the presence of 10 umol/1 unlabelled insulin.
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pmol glucose
incorporated
per 10 cm2
cell membrane
Insulin (mol/|)
Insulin (mol/l)
FIGURE 7.3 Insulin stimulation of lipogenesis shown as absolute
rates (top) and as percentage stimulation (bottom). Dotted
line indicates 50% stimulation.
Brittle (o—o) and stable (• • ) diabetics.
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FIGURE 7.4 Relationship between maximum specific insulin binding
and insulin concentration required for half-maximal
stimulation of lipogenesis in adipocytes from brittle (o)
and stable (•) diabetic subjects (Rg = 0.78; p<0.01).
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FIGURE 7.5 Specific insulin binding (top) and percentage
stimulation of lipogenesis (bottom) in one brittle
diabetic subject (Subject one in Table 7.3) during
intramuscular insulin therapy (•——•) and after 9 months of
intraperitoneal insulin administration (o~—o). Dotted lines
represent half-maximal displacement of insulin (top) and
50% maximal stimulation (bottom).
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DISCUSSION
The adipocyte insulin binding in the stable diabetic group was
not significantly different from that of the control group of non-
diabetic subjects. This is at variance with Pedersen's finding of
decreased adipocyte insulin binding in a group of stable insulin-
dependent diabetic patients (Pedersen & Hjollund 1982). It is
possible that the discrepancy in insulin binding data is a
consequence of the selection criteria used in the two studies, poorly
controlled stable diabetic subjects being specifically chosen as
controls for the brittle diabetic subjects in the present study.
Relative hypoinsulinaemia in these subjects could account for the
differing results, and indeed the mean fasting plasma free insulin
was only 50% of that reported by Pedersen. In the present study,
basal and maximal rates of lipogenesis and the insulin sensitivity of
lipogenesis were normal in the stable diabetic group. Normal
adipocyte sensitivity to insulin stimulation of lipogenesis has been
a consistant finding in studies of stable insulin-dependent diabetes
(Pedersen & Hjollund 1982, Yki-Jarvinen et_ al_ 1984) although the
sensitivity of adipocyte glucose transport has been reported to be
normal in some studies (Yki-Jarvinen et_ al_ 1984) and diminished in
others (Pedersen & Hjollund 1982). Yki-Jarvinen and colleagues (1984)
observed normal basal and maximal rates of lipogenesis and glucose
transport in adipocytes from moderately well controlled insulin-
dependent diabetic subjects. Pedersen and Hjollund (1982) observed
normal basal and maximal rates of glucose transport but decreased
rates of lipogenesis in an apparantly similar study.
It cannot be certain that the diet, insulin therapy and
metabolic control of the diabetic groups reported in different
studies are strictly comparable. Improvement in glycaemic control in
insulin-dependent diabetic subjects may be associated with an
increase in insulin sensitivity i_n vivo (Beck-Nielsen et_ al^ 1984). In
the present study, the stable diabetic subjects were more obese than
the normal control subjects, but this factor would have tended to
create rather than obviate differences in insulin binding and action.
The small difference in age between the two groups would not be
expected to influence the results, although studies of much older
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subjects have demonstrated an effect of age upon adipocyte insulin
sensitivity (Bolinder et^ al_ 1983, Fink et_ al_ 1983). The low-
carbohydrate diets of the diabetic subjects are representative of the
dietary intake of the majority of insulin-dependent diabetics at the
present time. The effect of a difference in habitual calorie intake
is unknown, and the absolute differences in carbohydrate and fat
intake are small compared to those shown to be able to influence
insulin binding (Ward et_ al_ 1982, Pedersen et_ al 1982b, Hjollund et_
al 1983a).
The brittle diabetic subjects were observed to have normal
adipocyte receptor number but reduced adipocyte insulin receptor
affinity and the reduction in affinity was reflected in resistance to
insulin stimulation of lipogenesis in vitro. The insulin dosage in
the brittle group was more than double that of the stable diabetic
group and the possibility of receptor down-regulation by insulin must
be considered. There was, however, no relationship between insulin
dose and maximum insulin binding within either group. Similarly
there was no relationship between insulin dose and half-maximal
stimulation of lipogenesis. Fasting plasma free insulin levels were
markedly higher in those brittle diabetic patients receiving insulin
by intravenous infusion (74 +_ 24 mU/1) rather than by intermittent
intramuscular injection (8.7 + 3.5 mU/1), but this bore no
relationship to the extent of the decrease in insulin binding or
insulin sensitivity. Furthermore, the mean fasting plasma free
insulin level was higher in the stable group than in the brittle
subjects receiving intramuscular insulin. Dietary factors have been
shown to influence cellular insulin binding (Ward et^ al^ 1982,
Hjollund et_ al^ 1983a) but the dietary differences between the brittle
diabetic group and the stable diabetic subjects were relatively small
and would not have been expected to affect insulin binding. The two
diabetic groups were well matched with respect to age and body
weight.
Previous studies In vivo and jln vitro have suggested that short-
term down-regulation of insulin receptors can be mediated by
reduction in cell surface receptor number (Marshall & Olefsky 1980,
Pezzino et al 1980). Studies of adipocyte insulin binding in various
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clinical states of insulin resistance have also suggested that
reduction in adipocyte insulin binding is most often a result of
reduced receptor number (Olefsky 1976, Olefsky et_ <il 1982, Pedersen &
Hjollund 1982). Short term changes in insulin receptor affinity have
been recorded after acute changes in food intake (Bar et^ al^ 1976,
Beck-Nielsen & Pedersen 1978, Livingston & Moxley 1982) and after
hydrocortisone (Yasuda & Kitabchi 1980) or growth hormone
administration (Bratusch-Marrain et^ al 1982). Examples of chronic
reduction in receptor affinity are rare, having been demonstrated
during high fat diets (Beck-Nielsen et_ al^ 1978), in one study of
obese subjects (Pedersen et_ al 1981c) and during glucocorticoid
administration in rats (Kahn et_ al^ 1978). The reduction of receptor
affinity observed in the group of brittle diabetics is therefore of
particular interest. The cause of this change in receptor affinity is
uncertain. No abnormalities in serum glucagon, growth hormone,
prolactin nor catecholamines have been observed in brittle diabetes
and although morning Cortisol levels have been noted to be somewhat
elevated, mean 24 hour serum Cortisol levels in the same subjects
were unremarkable (Massi-Benedetti et_ a^l 1984). Plasma non-
esterified fatty acid and total ketone body levels were observed to
be variable but not consistently high (Schade et^ al_ 1980). The
syndrome of brittle diabetes is intimately related to the
administration of extremely variable insulin doses over a long period
of time. As insulin itself appears to be a major factor regulating
the insulin receptor, the observation of an unusual adipocyte insulin
receptor status is perhaps not surprising.
It has been suggested that increased degradation of insulin in
the subcutaneous tissues may account for the poor response to
subcutaneous insulin characteristic of brittle diabetic patients
(Berger et_ al^ 1979, Gill et_ al_ 1984). The studies on insulin
degradation presented here demonstrate that the adipocytes themselves
are not responsible for any such abnormal degradation, although other
subcutaneous components could be involved in insulin degradation. The
similarity in insulin degradation in the presence of adipocytes from
each of the groups also eliminates this as a possible cause of the
observed low insulin binding to the cells of the brittle diabetic
patients.
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Although intramuscular insulin is sometimes effective in
achieving adequate plasma free insulin levels and reasonable
metabolic control in the short term (Pickup et al_ 1981 & 1983), this
is often not so and long term intravenous insulin may be required
(Berger et_ al_ 1979). Both of these routes induce hyperinsulinaemia in
the peripheral circulation, a factor which can be avoided at least in
part by peritoneal delivery of insulin (Schade et^ aJ 1980, Pozza et^
al 1983, Husband et_ al 1984). In one brittle patient restudied after
a 9 month period of satisfactory metabolic control on intraperitoneal
insulin therapy, adipocyte insulin binding reverted towards the mean
of the stable diabetic group secondary to an increase in receptor
affinity. In the patients restudied during treatment with continuous
intraperitoneal and intravenous insulin infusion, insulin receptor
affinity also appeared to increase, as evidenced by decreased insulin
concentrations required for half-maximum displacement of tracer
insulin. Despite this, maximum specific binding was not affected,
suggesting a simultaneously decreased receptor number. In all three
subjects, a decrease in the insulin concentration necessary to
achieve half-maximal stimulation was observed. Conventionally, this
may be taken to indicate increased cellular insulin sensitivity (Kahn
1978). However, a fall was observed in the maximally insulin
stimulated rate of adipocyte lipogenesis for all three subjects
during the period of stable control. This change during the period of
stable diabetic control is difficult to explain, and suggests the
development of a post-binding defect of insulin stimulation of
lipogenesis. The reversal of the abnormalities of binding affinity
and insulin sensitivity of brittle diabetes brought about by this
change in route of administration and dose of insulin indicates that
the reduced receptor affinity and adipocyte insulin resistance are
unlikely to be primary changes. Once present, however, these changes
are likely to exacerbate the clinical problems. Further study is
required to define the precise aspect of the abnormal metabolic state
which induces the cellular insulin resistance in brittle diabetes.
In conclusion, reduced adipocyte insulin receptor affinity and
reduced adipocyte insulin sensitivity have been observed in brittle
diabetes. These abnormalities were observed during treatment with
high doses of insulin administered intramuscularly or intravenously.
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No direct relationship of the tissue abnormalities to insulin dose or
to plasma free insulin levels could be established. The reversal of
the abnormalities during periods of stable diabetic control achieved
by continuous intra-peritoneal or intravenous insulin infusion
suggests that changes in tissue insulin sensitivity may not be the
primary cause of the syndrome.
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METHODOLOGY
Results of iri vivo and i^n vitro studies of insulin sensitivity
and responsiveness depend heavily upon the accuracy, precision and
relevance of the techniques used. Adipose tissue from the gluteal
region was used for all the clinical studies as it has been
demonstrated that adipocytes from different anatomical sites do not
display identical metabolic characteristics (Bolinder et al^ 1983b).
There is no evidence to suggest that the subcutaneous tissue of any
one region is more relevant to whole body metabolism than that of
other regions. The selection of the gluteal region is of practical
importance, adipose tissue biopsy being possible at this site even in
lean subjects. The potential effects of lignocaine upon adipocyte
cell membrane function must be considered, even though it was
injected intradermally rather than subcutaneously. However, multiple
injections of lignocaine into a biopsy sample was found not to affect
adipocyte function (Pedersen 1982).
The adipocyte insulin binding assay used in the present studies
had a high precision and was associated with low insulin degradation
and a lower non-specific binding than previously reported (Olefsky
1976, Harewood et a^l 1982, Pedersen 1983). Accuracy of the assay was
not formally determined, but Hjollund and colleagues (1983) found an
identical assay to be highly reproducible. Specific insulin binding
was measured at true steady state and thus represented a measure of
physiologically active insulin receptors. All insulin binding and
action data was related to adipocyte surface area, rather than cell
number. Adipocytes have a very thin rim of cytoplasm surrounding the
lipid store which occupies most of the cell volume. The surface area
may be anticipated to be more closely related to acute metabolic
changes than cell volume. Adipocytes from different individuals vary
markedly in size, and this influences any parameter expressed as a
function of cell number. Thus, the adipocytes of normal young males
and females appear to have different insulin binding capacities and
different basal and maximal rates of glucose transport and metabolism
if cell number, rather than surface area is used as denominator
(Pedersen et al 1982a). In contrast to studies comparing male and
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female or lean and obese subjects, mean cell diameter did not differ
between control and study groups in any of the present studies, and
hence expression of data per cell number, per cell volume or per cell
surface area would not affect the findings.
Insulin action upon isolated adipocytes was assessed by
measuring rates of glucose incorporation into total lipids. Glucose
uptake into the cell, conversion to glycerol phosphate and
esterification is therefore assessed. It is likely that glucose
uptake is the rate limiting step (Pedersen et_ al^ 1982a). When initial
rates of glucose transport were measured directly, the results agreed
with those of lipogenesis studies (Chapter 6). It may not be assumed
that the insulin sensitivity of any one metabolic pathway reflects
that of others. Glucose oxidation and lipolysis appear to be
differentially affected in insulin-dependent diabetes (Pedersen &
Hjollund 1982). However, storage of glucose as lipid rather than
inhibition of lipolysis is relevant to the processes involved in the
assessment of insulin sensitivity in vivo (lipogenesis and glycogen
synthesis). It would have been of interest to examine all aspects of
adipocyte insulin action in the present studies, but it was not
technically feasible to perform singlehandedly more than one insulin
action assay in addition to the binding studies upon each biopsy
sample.
The monocyte insulin binding assay compared favourably with
other published assays by the criteria of precision, tracer insulin
degradation, steady state binding and non-specific binding. Data on
accuracy of monocyte binding assays have not previously been
reported. All assays of blood cell insulin binding are performed at
sub-physiological temperatures, tracer insulin degradation being
excessively rapid at 37°C, and this factor could distance the in
vitro observations from iin vivo cellular receptor status. The effect
of assay temperature per se does not correct for the lack of
correlation with adipocyte insulin binding, Pedersen and Hjollund
(1982) having compared insulin binding to monocytes at 15°C and
adipocytes at both 15 and 37°C. Unlike adipocytes, monocytes bind
insulin with a pH optimum of 8.0 and all reported studies have been
carried out at this pH. Although this factor is unlikely to distort
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the results of comparative studies of disease states, it does imply a
lack of direct physiological relevance for monocyte insulin binding.
The term "monocyte insulin binding" is traditionally used to describe
the insulin binding properties of a mixed mononuclear cell
suspension. Lymphocytes comprise approximately 80% of the cell number
but account for less than 20% of the specific binding activity in
such a suspension. Large changes in lymphocyte number or properties
would thus be required to influence the capacity for insulin binding
observed in the mixed cell suspensions. Provided that the method for
determining the number of monocytes is accurate, then it may be
preferable to accept the implications of measurements upon the mixed
cell population rather than subject monocytes to lengthy and
metabolically perturbing separation techniques.
Several methods have been used for the assessment of insulin
sensitivity in vivo. The intravenous insulin tolerance test and the
oral glucose / subcutaneous insulin test both fail to establish
steady state insulin action, and secretion of counter-regulatory
hormones complicates interpretation of the former test. The
euglycaemic hyperinsulinaemic clamp technique allows assessment of
glucose disposal rates during steady state insulin action. The
insulin infusion rate chosen for the present studies generates
peripheral plasma insulin levels equivalent to normal post-prandial
levels. It has been shown that hepatic glucose output is decreased by
more than 90% under the clamp conditions in both normal and insulin
resistant subjects (DeFronzo e£ aT 1983a). Under conditions of
euglycaemic hyperinsulinaemia, glucose uptake by the peripheral
tissues is favoured, only 5 to 10% of an intravenously administered
glucose load being taken up by the splanchnic bed (DeFronzo et_ <il
1978b). The rate of glucose infusion thus reflects glucose uptake by
muscle and adipose tissue, muscle accounting for approximately 83% of
total glucose disposal (DeFronzo £t_ a_l 1981a). Valid comparison of
insulin mediated glucose disposal rates between different subject
groups depends heavily upon the steady state blood glucose levels and
upon the variablility of blood glucose during the clamp period. Both
of these factors were satisfactory in the present studies (Chapters 2
& 4).
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The ability of the euglycaemic clamp technique to distinguish
between marked degrees of insulin resistance at physiological levels
of hyperinsulinaemia is limited by the rate of non-insulin-dependent
glucose utilisation (approximately 1.5 mg/kg/min in normal subjects).
The glucose/insulin infusion technique avoids this difficulty, the
parameter measured - steady state blood glucose concentration -
having no fixed limits. In normal subjects, endogenous insulin
secretion is suppressed during the test. Although insulin secretion
occurs in subjects with raised steady state blood levels and
peripheral tissue glucose uptake is increased by a mass action effect
(DeFronzo et^ al^ 1983a), this should not impair distinction between
degrees of insulin resistance. It has been demonstrated that the
results of glucose/ insulin infusion and euglycaemic clamp correlate
well (Heine et_ al_ 1982) and hence it is unlikely that the magnitude
of any mass action effect could change the ranking of the cirrhotic
subjects with respect to degree of insulin resistance.
RELATIONSHIP BETWEEN DIFFERENT TISSUES
The overall metabolic response of the body depends upon the
integrated function of liver, muscle and adipose tissue. The
metabolic behaviour of each tissue is regulated both by hormonal
influence and substrate supply (Randle et al 1966). It is therefore
not surprising that one tissue should display hormonal responses
which are not reflected by other tissues. The disparate behaviour of
liver compared to peripheral tissues in hyperthyroidism (Chapter 6)
is an example of this and it cannot be assumed that one tissue
regulates any one step in cellular insulin action in precisely the
same manner as another tissue, particularly if hormonal and metabolic
environments differ markedly. The widespread assumption that
circulating monocytes reflect the insulin receptor status of insulin
sensitive tissues thus appears insubstantial on theoretical grounds
alone. It is noteworthy that only one relevant study is quoted to
support this hypothesis (Olefsky 1976). The hypothesis was indirectly
supported by consistant observations of low insulin binding to all
cell types in obesity, although the pitfalls in extrapolating from
these observations were discussed at the start of the era of clinical
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studies of blood cell insulin binding (Olefsky 1976). The data of
Pedersen and colleagues (1982a, Pedersen & Hjollund 1982) and the
data presented in Chapter 3 demonstrate that the monocyte cannot be
accepted as an accurate and convenient mirror of the insulin receptor
status of adipose tissue.
The assumed relevance to carbohydrate metabolism of blood cell
insulin receptor status has inhibited study of the physiological
function of insulin receptors on these cells. Several isolated
findings are of interest in this respect. Insulin receptors on non-
cytotoxic T-lymphocytes are not expressed unless the cells are
exposed to specific antigenic stimulation (Braciale et_ al^ 1982).
Insulin has been shown to influence the cell membrane fluidity of
erythrocytes (Bryszewska & Leyko 1983), and studies of the
physiological relevance and mechanism of this finding will be of
interest.
The two major peripheral insulin sensitive tissues, muscle and
fat are exposed to the same hormonal and metabolic influences. In
hepatic cirrhosis, obesity and insulin-dependent diabetes the low
adipocyte insulin receptor number and adipocyte insensitivity to
insulin appear to parallel the iti vivo observations on muscle insulin
sensitivity, as measured by the euglycaemic clamp technique (Iversen
et_ al^ 1984, Taylor et_ al 1984a, Olefsky et_ al 1982a, DeFronzo et al
1982, Pedersen & Hjollund 1982). In hyperthyroidism, the sensitivity
of both adipocytes ^Ln. vitro and muscle iri vivo were found to be
normal (McCulloch et^ al 1983a, Taylor et_ al_ 1984c). However, it may
not be inferred that adipocytes and myocytes always display similar
changes in insulin sensitivity in all clinical states. The
observation of differential sensitivity of antilipolysis and glucose
metabolism even in the same cell type (Pedersen & Hjollund 1982) does
suggest that general comparison of the insulin sensitivity of cells
of disparate metabolic function are unlikely to be well founded. The
normal adipocyte insulin sensitivity but impaired myocyte insulin
sensitivity in chronic renal failure (DeFronzo & Smith 1982, Chapter
5) may represent one example of different responses of the two
major peripheral tissues, although the possibility of circulating
inhibitors of insulin action in this condition (Dzurik et al 1969,
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Lockwood & McCaleb 1983) prevents direct comparability of in vivo and
in vitro studies. A more precise understanding of the relative
behaviour of adipocyte and myocytes must await the performance of
simultaneous in vitro studies upon the two cell types.
INTERPRETATION OF GLUCOSE TOLERANCE TEST DATA
The data presented in Chapters 4, 5 and 6 demonstrate a
notable lack of relationship between glucose tolerance and adipocyte
insulin sensitivity. In cirrhotic subjects, no relationship between
in vivo insulin sensitivity and glucose tolerance could be
demonstrated. These findings suggest that tolerance to oral glucose
depends upon peripheral tissue insulin sensitivity to only a small
extent. Direct measurement of splanchnic glucose balance during the
7 5 gram oral glucose tolerance test in normal subjects has shown that
50 - 60 / of the administered glucose is taken up by splanchnic
tissues (predominantly liver) (Waldhausl £t_ £l_ 1983), whereas only
10 % of an intravenously administered glucose load is taken up by the
liver (DeFronzo et^ jkl 1978b). This difference is not an effect of
glucose delivery to the liver via the portal vein, as approximately
90 % of orally administered glucose appears in the systemic
circulation (Radziuk et_ al_ 1978). Hollenbeck and colleagues (1984)
have estimated that peripheral tissue responses to insulin following
oral glucose account for only one third of the observed overall
response. Extrapolation of these studies to any pathological state is
complicated by variable hepatic insulin extraction and hence variable
peripheral plasma insulin levels (Bratusch-Marrain et_ al^ 1984).
Decreased hepatic insulin extraction in cirrhosis (Greco et^ al^ 1979,
Riggio et_ al^ 1982) may be expected to allow higher peripheral insulin
levels and hence a relatively greater effect upon peripheral tissues
were it not for the presence of peripheral tissue insulin resistance.
Porto-systemic shunting of blood per se does not appear to have a
marked influence upon glucose tolerance in cirrhosis (Johnston et^ al
1978).
Treatment of chronic renal failure by C.A.P.D. brings about a
decrease in fasting blood glucose, most likely as a secondary
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consequence of reduction in hepatic glucose output (DeFronzo et al
1983a). Fasting serum insulin levels remained unchanged after
C.A.P.D. implying that the liver had become more insulin sensitive.
Despite this, glucose tolerance remained abnormal, suggesting
impaired sensitivity of both liver and peripheral tissues at higher
insulin concentrations.
Hyperthyroidism provides an interesting model for the study of
hepatic function after an oral glucose load, peripheral insulin
sensitivity being normal in this condition (McCulloch et_ al^ 1983a).
The hyperglycaemia observed is therefore likely to be a direct
consequence of decreased hepatic glucose uptake. In hyperthyroid
subjects, high peak but almost normal two hour blood glucose
concentrations were observed. This could represent an effect of
peripheral tissues responding to the combination of hyperglycaemia
and normal plasma insulin levels, perhaps together with a greater
hepatic response at high plasma insulin levels. Study of the tissue
distribution of an oral glucose load in hyperthyroid subjects could
distinguish between these possibilities.
RELATIONSHIP BETWEEN RECEPTOR BINDING AND INSULIN ACTION IN
ADIPOCYTES
The original descriptions of low insulin receptor number on
monocytes in insulin resistant states led to the concept that
decreased insulin receptor number was a major cause of cellular
insensitivity to insulin action (Bar et_ al^ 1976, Olefsky & Kolterman
1982, Roth & Taylor 1982). The tendency during the 1970's to
introduce all papers upon blood cell insulin binding with the comment
that the first step in the action of peptide hormones consisted of
interaction of the hormone with specific cell surface receptors,
suggests an underlying belief that the first step was also the major
regulatory step. Recognition of states of cellular insulin resistance
characterised by normal insulin receptor number and affinity led to
the concept of rate-limiting steps in the intracellular pathways of
insulin action (Bollinder al_ 1982). The discovery of the protein
kinase activity of the insulin receptor (Roth & Cassel 1983) and the
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hypothesis of a cascade of phosphorylation / dephosphorylation
reactions conveying the insulin signal within the cell (Denton et al
1981) has indicated a mechanism for the linkage between receptor and
intracellular action, but the exact nature of this linkage remains
obscure.
Insulin receptor internalisation normally occurs simultaneously
with insulin action (Olefsky et_ al 1982b). Receptor downregulation by
insulin depends upon regulation of receptor internalisation and
recycling to the cell membrane. It has been postulated that post-
binding defects in insulin action may also bring about failure of
downregulation of insulin receptors (Caro & Amatruda 1980, Misbin et
al 1983). This hypothesis could explain the anomalous occurrence of
normal insulin receptor number but impaired cellular insulin action
in the presence of hyperinsulinaemia (Bolinder et_ al^ 1982). In
subjects with cryptogenic and primary biliary cirrhosis, adipocyte
insulin sensitivity was found to be impaired, but adipocyte insulin
receptor binding was only minimally decreased (Chapter 4).
The combination of decreased insulin receptor number and normal
cellular insulin sensitivity has only been observed in
hyperthyroidism (Chapter 6). Thyroid hormones, or some secondary
effect of excessive thyroid hormone levels, must act upon the
processes regulating receptor number, in addition to inducing
compensatory changes so that cellular insulin sensitivity remains
normal. These observations suggest that each of the steps of cellular
insulin action, receptor and post-binding, may be amenable to
separate regulation. Overall cellular insulin action must be regarded
as a chain of events, each link of which may be capable of being
regulated. The insulin receptor is but one link in this chain.
CONTROL OF CELLULAR INSULIN ACTION
Insulin was the first factor recognised to regulate insulin
receptor number (Gavin et al 1974). The concurrence of
hyperinsulinaemia and insulin resistance was postulated to be a
reflection of the role of hyperinsulinaemia in the genesis of
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cellular insulin resistance (Bar et^ al_ 1976). The proposed model was
based upon a circular argument, involving hyperinsulinaemia,
decreased insulin receptor number, decreased insulin action,
hyperglycaemia and hence hyperinsulinaemia. The initiating factors
have never been identified. Short-term insulin infusion in_ vivo does
indeed induce a degree of adipocyte insulin resistance (Mandarino ££
al 1984), but glucose administration orally or intravenously to
normal subjects is associated with a pronounced increase in adipocyte
insulin sensitivity (Arner et_ aT 1983, Livingston et_ al_ 1984). Eight
day infusion of insulin into rats has been reported to increase both
in vivo insulin sensitivity and in vitro adipocyte insulin
sensitivity (Trimble £t_ al_ 1984). It is apparent that insulin is only
one regulator of cellular insulin sensitivity, and that the acute and
chronic effects of other hormones and of substrate supply upon
individual tissues must be evaluated.
The integrated effects of insulin and metabolic state are of
relevance to insulin-dependent diabetes. Poor diabetic control is
associated with insulin resistance both in vivo and in isolated
adipocytes, whereas during periods of optimal control normal insulin
sensitivity is observed (Pedersen & Hjollund 1982, Lonnroth £t^ al_
1983b, Hjollund et^ al_ 1983a, Reevers et_ a_l 1984). Insulin resistance
and poor control was observed in brittle diabetes (Chapter 7).
Restoration of stable control on a lower daily insulin dose brought
about an increase in adipocyte insulin sensitivity. This was achieved
by alteration not only of total insulin dosage but also of route and
temporal pattern of insulin delivery. In the small number of subjects
restudied, the difference between administration of insulin
intraperitoneally or intravenously in terms of adipocyte function was
not great. The constant rate of insulin infusion may have been
expected to have a lesser biological effect than a regimen employing
intermittent insulin boluses (Matthews et al 1984).
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PATHOPHYSIOLOGY OF INSULIN RESISTANCE IN METABOLIC DISEASE
The in vivo defect in insulin sensitivity identified in subjects
with hepatic cirrhosis was found to be reflected in adipocyte
behaviour in vitro. However, the observation of marked differences
between the aetiological sub-groups of cirrhotic subjects complicates
interpretation of data. Both insulin receptor and post-binding
defects in insulin action were evident in adipocytes from subjects
with alcoholic cirrhosis. Insulin receptor number was only slightly
decreased but insulin sensitivity was markedly impaired in adipocytes
from subjects with primary biliary and cryptogenic cirrhosis. The
severity of impairment of liver function was similar in all three
subgroups as judged by the usual clinical and metabolic criteria. The
effect of alcohol, either directly or secondarily via hormonal or
metabolic effects, is most relevant to these findings. Chronic and
excessive alcohol intake has been reported to be associated with mild
elevation of plasma Cortisol (Margraf et_ al_ 1967) and catecholamines
(Ogata et al 1971) and with impaired regulation of growth hormone
secretion (Chalmers et^ al^ 1977). Episodic hypoglycaemia and
normoglycaemic ketoacidosis may be frequent and underdiagnosed in
chronic alcoholics (Marks 1978, Palmer 1983). Comparison of
adipocytes from age, sex, weight and diet matched groups of non-
cirrhotic and cirrhotic alcoholics could identify the separate
effects of cirrhosis and chronic alcohol intake.
The insulin action data have been discussed in terms of insulin
sensitivity of adipocytes as represented by the insulin concentration
necessary to achieve half-maximal stimulation (Kahn 1978).
Responsiveness, defined as the absolute increase above basal rates,
was found to be paradoxically greater in the primary biliary and
cryptogenic subgroups. The implications of this are uncertain
particularly as exaggerated rates of lipogensis would not occur at
physiological insulin levels. Maximal rates of lipogenesis as
measured iri vitro must be regarded as a theoretical concept. If it is
assumed that the differences between the subgroups in subject
matching are relatively unimportant, then the parameter of insulin
action which agrees most closely with data from the Ln vivo studies
is that of sensitivity. The insulin concentration achieving half-
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maximal stimulation of lipogenesis also appeared more relevant to in
vivo insulin sensitivity in hyperthyroid subjects, uraemic subjects
on C.A.P.D., and brittle diabetic subjects after restoration of
stable control. This interpretation assumes that the insulin
sensitivity of muscle and fat are similarly regulated ija vivo. At the
present time, the conventional interpretation of insulin action data
cannot be rejected in favour of a more satisfactory system.
The role of elevated serum insulin levels in bringing about
adipocyte insulin receptor downregulation in cirrhosis must be
considered in view of the correlation between serum insulin and
adipocyte insulin binding. However, it is possible that a decrease in
insulin receptor number induced the hyperinsulinaemia. The lack of
relationship between either mean serum insulin or in vivo insulin
sensitivity and insulin receptor status of the cirrhotic subgroups
suggests that post-binding abnormalities of insulin action play the
more important role in peripheral tissue insulin insensitivity in
cirrhosis. The isolation and partial chracterisation of a circulating
inhibitor of insulin action (Dzurikova et^ aT 1974) raises interesting
questions about the influence of such a substance upon the post-
binding pathways of insulin action.
In chronic renal failure, iri vivo studies have demonstrated
clearly that insulin action upon muscle is decreased (Westervelt
1969, DeFronzo & Smith 1982). The present observation of normal Tn
vitro adipocyte insulin sensitivity may be interpreted as supporting
the concept of a circulating inhibitor of insulin action (Dzurik et_
al 1969, Lockwood & McCaleb 1983). Sudden removal of this inhibitor
could account for the slightly greater iii vitro sensitivity of
adipocytes from uraemic subjects. If C.A.P.D. decreased circulating
levels of any such inhibitor, then the moderate right shift of dose
response curve for stimulation of lipogensis (Figure 5) could be
explained, compensation for the inhibitory influence no longer being
induced. The probable greater sensitivity of the liver to insulin in
the suppression of fasting hepatic glucose output could be speculated
to be an effect of the removal by dialysis of an inhibitor of insulin
action. If the in vitro binding studies are assumed to reflect in
vivo insulin receptor status, then within the physiological range of
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insulin concentrations the increase in affinity would compensate for
the decrease in receptor number. Hence, any impairment of insulin
sensitivity would be due entirely to post-binding defects. This
conclusion may be supported by data from multi-step hyper-
insulinaemic, euglycaemic clamp studies, and the observed phenomena
could be explained without the need to adduce abnormalities of
overall insulin receptor function. However, the direct relevance of
adipocyte insulin receptor studies will remain uncertain until the
proposed inhibitor of insulin action is characterised. If an
inhibitor competitively interferes with insulin binding as reported
by Milutinovic (1983), then measurement of binding in vitro may be
expected to be associated with increased affinity.
The finding of normal insulin sensitivity in adipocytes from
hyperthyroid subjects is complemented by the observation of normal
peripheral tissue insulin sensitivity in vivo (McCulloch et_ al
1983a). There can be little doubt that the abnormalities of
carbohydrate metabolism in hyperthyroidism are mainly a result of
altered hepatic function. A low adipocyte insulin receptor number
suggests an effect of elevated thyroid hormone levels upon regulation
of cellular insulin receptor number and also that such an effect can
be wholly compensated by post-binding modulation of the insulin
signal.
Decreased receptor affinity was demonstrated in adipocytes from
brittle diabetic subjects, and this appeared to correlate with
decreased adipocyte insulin sensitivity. Although there is no
evidence to suggest any post-binding defect, it is not possible to
declare that the intracellular pathways of insulin action are normal
in adipocytes from these subjects. However, the data obtained are
consistent with a receptor defect. It is possible that the abnormal
pattern of insulin administration brings about the observed changes,
although attempts to induce receptor defects in normal subjects by
constant insulin infusion have been unsuccessful (Mandarino et al
1984), post-binding defects in insulin action being induced instead.
This suggests that insulin could exert a primary effect upon
intracellular mechanisms, and that observed receptor changes may be
secondary to intrinsic cellular control mechanisms (Caro & Amatruda
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1980, Misbin £t al_ 1983). Although the abnormalities in the
adipocytes of brittle diabetic subjects are of considerable interest,
they appear unlikely to be directly related to the primary cause of
the syndrome.
In summary, the results of these studies emphasise the
importance of the intracellular steps of insulin action in determining
the response of individual tissues in metabolic disease. The role of
the insulin receptor as the initiator of a series of intracellular
events is confirmed, and the need is clear for detailed study of the
control of each post-binding step of insulin action.
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APPENDIX ONE: COMPOSITION OF BUFFERS
Collagenase buffer
NaCl 135 mmol/1
KC1 4.8 mmol/1
MgS04 1.7 mmol/1
CaCl 2
2.5 mmol/1
NaH2P04 0.2 mmol/1
Na2HP04 1.0 mmol/1
HEPES 10 mmol/1
Glucose 5 mmol/1
Human serum albumin 25 mg/ral
Crude collagenase 0.5 mg/ml
pH 7.42 at 37°C
Lipogenesis buffer
Used for washing adipocytes and for assays of glucose transport and
lipogensis in adipocytes.
NaCl 135 ramol/1
KC1 4.8 mmol/1
MgS04 1.7 mmol/1
CaCl2 2.5 mmol/1
NaH2P04 0.2 mmol/1
Na2HP04 1.0 mmol/1
HEPES 10 mmol/1
Human serum albumin 50 mg/ml
pH 7.42 at 37°C
Receptor buffer
Used for assay of insulin binding to adipocytes.
NaCl 135 mmol/1
KC1 4.8 mmol/1
MgS04 1.7 mmol/1
CaCl 2 2.5 mmol/1
NaH2P04 0.2 mmol/1
Na2HP04 1.0
HEPES 10 mmol/1
Glucose 0.5 mmol/1
Human serum albumin 50 mg/ml
pH 7.42 at 37°c
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Monocyte binding buffer
NaCl 120 mmol/1
KC1 5.0 mmol/1
MgS04 1.2 mmol/1
Na acetate 15 mmo1/1
EDTA 1.0 mmol/1
Bacitracin 0.5 mg/ml
Bovine serum albumin
(Fraction V) 10 mg/ml
pH 8.0 at 20°C
APPENDIX TWO: LIST OF ABBREVIATIONS
A.M.P.
A.S.T.
C.A.P.D.
cm
C-peptide
°C
D-(U-14C)
E.D.T.A.
g
HbA,
125 j
I.B.W.
I.R.I.
kg
1
LG
max
mg
min
ml
mmol
mU
pCi
pm
P1
N.I.D.D.
nmol
N.S.
P
P.B.C.
P.F.I.
pH
pmol
P.T.H.
R
Rs
sec
vs
adenosine monophosphate
aspartate transaminase
continuous ambulatory peritoneal dialysis
centimetre
connecting peptide
degrees centigrade
Dextro isomer uniformly labelled with carbon
ethylenediamine tetra-acetic acid
unit gravity
glycosylated haemoglobin
iodine 125
ideal body weight
immunoreactive insulin
kilogram
litre
lipogenesis
maximum
milligram
minute
millilitre
millimole
milliunit
microcurie
micrometre
microlitre
non-insulin dependent diabetic
nanomole
not significant
probability
primary biliary cirrhosis
plasma free insulin
log hydrogen ion concentration
picomole
parathyroid hormone
linear correlation coefficient
Spearman rank correlation coefficient
second
versus
APPENDIX THREE: SOURCE OF MATERIALS USED
Albumin, bovine Fraction V
Albumin, bovine >99% pure
Albumin, human >99% pure
Bacitracin
Collagenase, crude
Collagenase, crude
Cover slide, plastic
Fenwal triple pack
Ficoll, M.W. 400,000
Glucose, D-(U-^C)
S.A. 270 Ci/mol
Haemaccel
Hepes
Hypaque, 65%
Infusaid pump
Insulin, crystalline porcine
1 ? S
Insulin, A^- I,
S.A. 210-240 pCi/ug
Medium 199
Naphthyl acetate
Nylon mesh, 20 denier tights
Pipe cleaners, Pathfinder
Pararosanilin hydrochloride
Phloretin
Siemens pump
Silicone oil 200/50 cs
Sutures, Vicryl and catgut
Trypan blue
Tubes, polypropylene and
polystyrene
Sigma Chemical Company Ltd, Poole,
Dorset
Hoechst UK Ltd, Houndslow, Middlesex
Hoechst UK Ltd, Houndslow, Middlesex
Sigma Chemical Company Ltd, Poole,
Dorset
P-L Biochemicals, Milwaukee, Wisconsin
U.S.A.
Worthingron Biochemical Corp, Freehold
New Jersey, U.S.A.
Micropure Holland, Rijsenburg, Holland
Travenol Labs Ltd, Thetford, Norfolk
Sigma Chemical Company Ltd, Poole,
Dorset
Amersham International, Little
Chalfont, Buckinhamshire
Hoechst UK Ltd, Houndslow, Middlesex
Sigma Chemical Company Ltd, Poole,
Dorset
Sterling Research Labs, Surbiton upon
Thames, Surrey
Infusaid Corporation, Norwood,
Massachussetts, U.S.A.
Novo Research Institute, Copenhagen,
Denmark
Novo Research Institute, Copenhagen,
Denmark
Flow Laboratories, Irvine, Ayrshire
Sigma Chemical Company Ltd, Poole,
Dorset
Marks & Spencer, Baker St, London
Robert Sinclair Ltd, Leeds
Sigma Chemical Company Ltd, Poole,
Dorset
Sigma Chemical Company Ltd, Poole,
Dorset
Siemens, Erlangen, West Germany
Dow Corning Corporation, Midland,
Michigan U.S.A.
Ethicon Ltd, Edinburgh
Sigma Chemical Company Ltd, Poole,
Dorset
Sarstedt Ltd, Leicester
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